WO2020038377A1 - 一种核酸、含有该核酸的药物组合物和缀合物及其用途 - Google Patents

一种核酸、含有该核酸的药物组合物和缀合物及其用途 Download PDF

Info

Publication number
WO2020038377A1
WO2020038377A1 PCT/CN2019/101656 CN2019101656W WO2020038377A1 WO 2020038377 A1 WO2020038377 A1 WO 2020038377A1 CN 2019101656 W CN2019101656 W CN 2019101656W WO 2020038377 A1 WO2020038377 A1 WO 2020038377A1
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
nucleotide
group
nucleotide sequence
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/101656
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
张鸿雁
高山
康代武
陈庚容
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ribo Life Science Co Ltd
Original Assignee
Suzhou Ribo Life Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Ribo Life Science Co Ltd filed Critical Suzhou Ribo Life Science Co Ltd
Priority to US17/269,039 priority Critical patent/US11918600B2/en
Priority to CN201980010175.1A priority patent/CN111655849B/zh
Priority to JP2021509880A priority patent/JP2021533800A/ja
Priority to EP19851738.5A priority patent/EP3842534A4/en
Publication of WO2020038377A1 publication Critical patent/WO2020038377A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

  • the present disclosure relates to an siRNA, pharmaceutical compositions and conjugates containing the same, and uses thereof. Specifically, the present disclosure relates to an siRNA for inhibiting the expression of a hepatitis B virus (HBV) gene, a pharmaceutical composition and a conjugate containing the siRNA as an active ingredient, and the siRNA and a drug combination Of conjugates and conjugates in the manufacture of a medicament for the prevention and / or treatment of hepatitis B.
  • HBV hepatitis B virus
  • Hepatitis B virus also known as Hepatitis B or Hepatitis B
  • Hepatitis B is a type of infectious disease that seriously threatens the world, especially China.
  • the two major classes of hepatitis B prevention and treatment drugs globally recognized are interferon and nucleoside analogs.
  • There are many disadvantages such as prone to drug resistance or limited use after use, such as interferon prone to adverse reactions, nucleoside drugs tolerant and relapse after discontinuation. Therefore, if the gene expression of the virus is silenced at the gene level, blocking the generation and replication of HBV, thereby fundamentally reducing the virus metabolism and the infection of liver cells, will undoubtedly be the most ideal treatment for hepatitis B.
  • Small interfering RNA can be based on the mechanism of RNA interference (RNAiference) to suppress or block any gene of interest (such as genes that cause diseases such as cancer) in a sequence-specific manner. Expression, so as to achieve the purpose of treating diseases.
  • RNAiference RNA interference
  • siRNA stabilization modification and its delivery system are two key technologies in the development of small RNA drugs.
  • the present disclosure provides an siRNA that can specifically target the P gene region, which is one of the four open reading frames of the HBV gene, thereby significantly inhibiting the expression of the HBV gene.
  • the siRNA provided by the present disclosure contains a sense strand and an antisense strand, and each nucleotide of the sense strand and the antisense strand is a modified nucleotide, wherein the sense strand and the antisense strand each include a fluoro-modified nucleotide And non-fluorine-modified nucleotides, said fluoro-modified nucleotides refer to nucleotides in which the hydroxyl group at the 2 'position of the ribose group of a nucleotide is replaced by fluorine, and the non-fluorine-modified nucleotides refer to the nucleus A nucleotide or nucleotide analog formed by substitution of a hydroxyl group at the 2 ′ position of a ribosyl group of a nucleotide with a non-fluorine group; the sense strand contains nucleotide sequence 1 and the antisense strand contains nucleotide sequence 2
  • the nucleotide sequence 1 includes a nucleotide Z A at a position corresponding to Z
  • the nucleotide sequence 2 includes a nucleotide Z ' B at a position corresponding to Z', where Z ' B is the The first nucleotide at the 5 'end of the antisense strand, and,
  • the fluoro-modified nucleotides are located in nucleotide sequence 1 and nucleotide sequence 2, no more than 5 fluoro-modified nucleotides in nucleotide sequence 1, and, according to the 5 'end to 3
  • the direction of the 'end, the nucleotides at positions 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified nucleotides; there are not many fluoro-modified nucleotides in the nucleotide sequence 2 Less than 7, and the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence 2 are fluoro-modified nucleotides.
  • the nucleotide sequence 1 is not more than 1 nucleotide difference between the nucleotide sequence shown in SEQ ID NO: 1 and / or the nucleotide sequence 2 is shown in SEQ ID NO: 2 No more than 1 nucleotide difference between the nucleotide sequences.
  • nucleotide differences between the nucleotide sequence comprises 2 'difference at the B site, and Z' Z B is selected from U, C or G.
  • Z A is a nucleotide complementary to Z ' B.
  • the nucleotide sequence 1 and the nucleotide sequence 2 are substantially reversely complementary, substantially completely reversely complementary, or completely reversely complementary; the substantially reverse complementation refers to between two nucleotide sequences There are no more than 3 base mismatches; said substantially complete reverse complementation means that there is no more than 1 base mismatch between two nucleotide sequences; complete reverse complementation means two There are no mismatches between the nucleotide sequences.
  • the sense strand also contains nucleotide sequence 3
  • the antisense strand also contains nucleotide sequence 4, and each of the nucleotide sequence 3 and the nucleotide sequence 4 is 1-4 nucleosides in length Acid, the nucleotide sequence 3 is linked to the 5 'end of the nucleotide sequence 1, and the nucleotide sequence 4 is linked to the 3' end of the nucleotide sequence 2, the nucleotide Sequence 3 and nucleotide sequence 4 are equal in length and are substantially completely reverse complementary or completely reverse complementary; the substantially complete reverse complement refers to the presence of no more than one between two nucleotide sequences Base mismatch; complete reverse complementation means that there is no mismatch between two nucleotide sequences.
  • the nucleotide sequence 3 and the nucleotide sequence 4 are each 1 nucleotide in length, and the base of the nucleotide sequence 3 is G; or,
  • the length of the nucleotide sequence 3 and the nucleotide sequence 4 are 2 nucleotides, and the bases of the nucleotide sequence 3 are U and G in order from the 5 ′ end to the 3 ′ end; or,
  • the length of the nucleotide sequence 3 and the nucleotide sequence 4 are 3 nucleotides. According to the direction from the 5 ′ end to the 3 ′ end, the bases of the nucleotide sequence 3 are U, U and G; or,
  • the length of the nucleotide sequence 3 and the nucleotide sequence 4 are 4 nucleotides. According to the direction from the 5 ′ end to the 3 ′ end, the bases of the nucleotide sequence 3 are A, U, U, and G.
  • the siRNA further contains a nucleotide sequence 5 which is 1 to 3 nucleotides in length and is connected to the 3 ′ end of the antisense strand, thereby constituting 3 of the antisense strand. 'Outstanding end.
  • the length of the nucleotide sequence 5 is 2 nucleotides, and in the direction from the 5 ′ end to the 3 ′ end, the nucleotide sequence 5 is 2 consecutive thymine deoxyribonucleotides, continuous Two uracil ribonucleotides, or two nucleotides complementary to the target mRNA.
  • the nucleotide sequence 1 contains the nucleotide sequence shown in SEQ ID NO: 3 or SEQ ID NO: 4, and the nucleotide sequence 2 contains SEQ ID NO: 5, SEQ ID NO: 6, Any one of the nucleotide sequences in the group consisting of the nucleotide sequences shown in SEQ ID NO: 7 and SEQ ID ID NO: 8:
  • the siRNA is any one of the following siP1-siP4:
  • Antisense strand 5'-AAUUCGUUGACAUACUUUCUU-3 '(SEQ ID NO: 5),
  • Antisense strand 5'-AAUUCGUUGACAUACUUUCCA-3 '(SEQ ID NO: 6),
  • Antisense strand 5'-UAUUCGUUGACAUACUUUCUU-3 '(SEQ ID NO: 7),
  • Antisense strand 5'-UAUUCGUUGACAUACUUUCCA-3 '(SEQ ID NO: 8),
  • the nucleotides at positions 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified nucleotides, and The remaining nucleotides in the sense strand are non-fluorinated nucleotides; and, in the antisense strand, the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence 2 Is a fluoro-modified nucleotide, and the rest of the nucleotides in the antisense strand are non-fluorine-modified nucleotides; or
  • the nucleotides at positions 5, 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified nucleotides, and The nucleotides at the remaining positions in the sense strand are non-fluorinated nucleotides; and in the antisense strand, positions 2, 6, 8, 9, 14, and 16 of the nucleotide sequence 2
  • the nucleotides are fluoro-modified nucleotides, and the remaining positions in the antisense strand are non-fluorine-modified nucleotides; or
  • the nucleotides at positions 5, 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified nucleotides, and The remaining nucleotides in the sense strand are non-fluorinated nucleotides; and, in the antisense strand, the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence 2 Is a fluoro-modified nucleotide, and the rest of the nucleotides in the antisense strand are non-fluorine-modified nucleotides.
  • Each non-fluorinated modified nucleotide is independently selected from one of nucleotides or nucleotide analogs in which the hydroxyl group at the 2 ′ position of the ribose group of the nucleotide is replaced with a non-fluorine group.
  • a nucleotide formed by substitution of a hydroxyl group at the 2 'position of a ribose group of a nucleotide with a non-fluorine group is selected from 2'-alkoxy-modified nucleotides, 2'-substituted alkoxy-modified nucleotides , 2'-alkyl-modified nucleotides, 2'-substituted alkyl-modified nucleotides, 2'-amino-modified nucleotides, 2'-substituted amino-modified nucleotides, 2 One of '-deoxynucleotides; the nucleotide analog is selected from one of isonucleotides, LNA, ENA, cET, UNA, and GNA.
  • Each non-fluorine-modified nucleotide is a methoxy-modified nucleotide
  • the methoxy-modified nucleotide refers to a nucleotide formed by the substitution of the 2′-hydroxy group of a ribose group with a methoxy group .
  • At least one of the phosphate groups in the phosphate-sugar backbone of at least one single strand in the sense and antisense strands of the siRNA of the present disclosure is a phosphate group having a modification group.
  • the phosphate group having a modifying group is a phosphorothioate group in which at least one oxygen atom in a phosphodiester bond in the phosphate group is replaced by a sulfur atom; in some embodiments, the phosphate group having a modifying group is a thiophosphate group having a structure represented by formula (1):
  • At least one of the group consisting of the following nucleotide linkages is a phosphorothioate linkage:
  • the 5 'terminal nucleotide of the siRNA antisense strand of the present disclosure is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide; in some embodiments, the 5' terminal The nucleotide is a nucleotide represented by any one of the following formulae (2) to (6):
  • R represents a group selected from the group consisting of H, OH, F, and methoxy
  • Base represents a base selected from A, U, C, G, or T.
  • the siRNA described in the present disclosure is the siRNA shown in any one of Tables 1A-1D.
  • the present disclosure provides a pharmaceutical composition containing the siRNA according to the present disclosure as an active ingredient and a pharmaceutically acceptable carrier.
  • the weight ratio of the siRNA to the pharmaceutically acceptable carrier is 1: (1-500), and may be 1: (1-50), for example.
  • the pharmaceutically acceptable carrier comprises an organic amine, a helper lipid, and a PEGylated lipid; wherein the organic amine is a compound represented by formula (201) and / or a pharmaceutically acceptable carrier thereof.
  • X 101 and X 102 are each independently O, S, NA or CA, where A is hydrogen or a C 1 -C 20 hydrocarbon chain;
  • R 101 , R 102 , R 103 , R 104 , R 105 , R 106 and R 107 are each independently hydrogen, cyclic or acyclic, substituted or unsubstituted, branched or straight chain aliphatic group Group, cyclic or acyclic, substituted or unsubstituted, branched or linear heteroaliphatic group, substituted or unsubstituted, branched or linear acyl, substituted or unsubstituted Substituted, branched or linear aryl, substituted or unsubstituted, branched or linear heteroaryl;
  • x is an integer from 1-10;
  • n is an integer of 1-3, m is an integer of 0-20, and p is 0 or 1; and wherein, when m and p are both 0, R 102 is hydrogen;
  • R 103 and nitrogen in formula (201) form a structure as shown in formula (202) or formula (203):
  • g, e, and f are each independently an integer of 1-6, "HCC” represents a hydrocarbon chain, and each * N represents a nitrogen atom shown in Formula (201).
  • the organic amine is an organic amine represented by formula (214) and / or an organic amine represented by formula (215):
  • the auxiliary lipid is cholesterol, an analog of cholesterol, and / or a derivative of cholesterol;
  • the PEGylated lipid is 1,2-dipalmitamide-sn-glycerol-3-phosphatidylethanolamine-N- [methoxy (polyethylene glycol)]-2000.
  • the molar ratio between the organic amine, the auxiliary lipid and the PEGylated lipid is (19.7-80): (19.7-80): (0.3-50).
  • the molar ratio between the organic amine, the auxiliary lipid and the PEGylated lipid is (50-70): (20-40): (3-20 ).
  • the present disclosure provides an siRNA conjugate comprising the siRNA according to the present disclosure as an active ingredient, and a ligand conjugated to the siRNA.
  • the ligand is a pharmaceutically acceptable conjugate group
  • the conjugate group comprises a pharmaceutically acceptable targeting group and a linker
  • the siRNA, the linker and the The targeting groups are sequentially covalently or non-covalently linked.
  • the joint has a structure as shown in formula (301):
  • k is an integer from 1-3;
  • L A is a chain-like moiety including an amide bond having a structure as shown in formula (302), and each of the L A is in an ether bond phase with one of the targeting group and the L C moiety at its two ends, respectively.
  • L B having the formula (303) comprises a pyrrolidine N- acyl chain portion shown structure, the linear portion having a carbonyl group at one end thereof and connected with the L C moiety through an amide bond, at the other end Has an oxygen atom and is connected to the siRNA through a phosphate bond:
  • the linker is connected to the 3 'end of the sense strand of the siRNA.
  • the targeting group is a ligand of an asialoglycoprotein receptor.
  • the targeting group is galactose or N-acetylgalactosamine.
  • the siRNA conjugate has a structure represented by formula (305):
  • double helix structure represents the siRNA
  • the linker is connected to the 3 'end of the sense strand of the siRNA.
  • the joint has a structure represented by formula (306):
  • l is an integer from 0 to 3;
  • # Indicates a site on the linker connected to the siRNA through a phosphate bond.
  • the linker is connected to the 3 'end of the sense strand of the siRNA.
  • the targeting group is a ligand of an asialoglycoprotein receptor.
  • the targeting group is galactose or N-acetylgalactosamine.
  • the siRNA conjugate has a structure represented by formula (307):
  • double helix structure represents the siRNA
  • the linker is connected to the 3 'end of the sense strand of the siRNA.
  • the present disclosure provides an siRNA conjugate represented by formula (401),
  • n1 is an integer selected from 1-3, and n3 is an integer selected from 0-4;
  • n1, m2 and m3 are independently an integer selected from 2-10;
  • R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are each independently one of H, methyl or ethyl;
  • R 3 is a group of the structure shown by Formula A59:
  • E 1 is OH, SH or BH 2
  • Nu is the above-mentioned siRNA provided by the present disclosure
  • R 2 is any group capable of achieving connection with N on the nitrogen-containing skeleton and with A59;
  • Each L 1 is independently selected from a combination of one or more of the groups of the formula A1-A26:
  • R ' is C 1 -C 10 alkyl
  • Ra is selected from one of the groups of formula A27-A45:
  • Rb is C 1 -C 10 alkyl
  • Each M 1 is selected from one of ligands having an affinity for the asialoglycoprotein receptor on the surface of mammalian liver cells.
  • L 1 is selected from a connection combination of at least two of A1, A4, A8, A10, and A11;
  • L 1 is selected from a combination of at least two of A1, A8, and A10.
  • the siRNA conjugate according to the above wherein the length of L 1 is 3-25 atoms, and the length of L 1 refers to the atom connected to the N atom in the nitrogen-containing skeleton to the The number of chain-forming atoms on the longest atomic chain formed by the M 1 connected atom;
  • L 1 is 4-15 atoms in length.
  • j1 is an integer of 2-10
  • j2 is an integer of 2-10
  • R ′ is a C 1 -C 4 alkyl group
  • Ra is A27, One of A28, A29, A30, and A31
  • Rb is a C 1 -C 5 alkyl group
  • j1 is an integer of 3-5
  • j2 is an integer of 3-5
  • R ' is one of methyl, ethyl, and isopropyl
  • Ra is A27 or A28
  • Rb is methyl, ethyl, or iso One of propyl and butyl.
  • each M 1 is independently selected from the group consisting of D-mannanose, L-mannanose, D-arabinose, and D-furanyl xylose , L-furan xylose, D-glucose, L-glucose, D-galactose, L-galactose, ⁇ -D-furan mannose, ⁇ -D-furan mannose, ⁇ -D-pyranomannose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-fructofurose, ⁇ -D- Fructofuran, ⁇ -D-galactopyranosyl, ⁇ -D-galactopyranosyl, ⁇ -D-galactopyranofuran, ⁇ -D-gal
  • each M 1 is N-acetylgalactosamine.
  • the site connected to N on the nitrogen-containing backbone on R 2 forms an amide bond with N
  • the site connected to P on R 3 forms a phosphate ester bond with P
  • R 2 may be selected from B5, B6, B5 ', or B6':
  • the siRNA conjugate according to the above wherein the conjugate has the formula (403), (404), (405), (406), (407), (408), (409 ), (410), (411), (412), (413), (414), (415), (416), (417), (418), (419), (420), (421), or (422)
  • P in Formula A59 is connected to the end of the sense strand or the antisense strand, or P in Formula A59 is connected to the 3 'end of the sense strand.
  • the present disclosure provides the siRNA as described above, the pharmaceutical composition as described above, and / or the siRNA conjugate as described above for use in the treatment and / or prevention by the hepatitis B virus Use of medicines for pathological conditions or diseases caused by infections.
  • the pathological condition or disease caused by infection with the hepatitis B virus is selected from chronic liver disease, hepatitis, liver fibrosis disease, or liver proliferative disease.
  • the present disclosure provides a method of treating and / or preventing a pathological condition or disease caused by a hepatitis B virus infection, the method comprising administering to a patient an effective amount of The pharmaceutical composition described above and / or the siRNA conjugate as described above.
  • the present disclosure provides a method of inhibiting HBV gene expression in hepatitis cells, which method comprises administering an effective amount of an siRNA as described above, a pharmaceutical composition as described above, and / or an siRNA as described above
  • the conjugate is contacted with hepatitis B virus-infected hepatitis cells.
  • the present disclosure provides a kit comprising a siRNA as described above, a pharmaceutical composition as described above, and / or a siRNA conjugate as described above.
  • the siRNA provided by the present disclosure has high plasma stability and good inhibitory activity. In some embodiments, the siRNA provided by the present disclosure is stable in human plasma in vitro for 72 hours without degradation; in some embodiments, the siRNA provided by the present disclosure has an in vitro inhibitory activity of more than 80% at a concentration of 0.1 nM.
  • the conjugates containing the siRNA provided by the present disclosure have lower off-target effects, better lysosomal stability, and / or inhibitory activity.
  • the conjugate containing the siRNA provided by the present disclosure can effectively target the liver and exhibit excellent characteristics of inhibiting HBV gene expression: while having a low off-target effect, it can be used at a single dose of 1 mg / kg HBV mRNA in the liver of HBV model mice was inhibited at the doses administered.
  • the conjugate containing the siRNA provided by the present disclosure can also effectively reduce the expression of HBV surface antigen in HBV model mice.
  • HBV surface antigen and HBV DNA inhibition The rate can reach more than 90%. Even after reaching the observation end point for 154 days, neither of these two indicators returned to the pre-dose level, HBsAg still had an inhibition rate of 77.0%, and HBV DNA still had an inhibition rate of 80.1%.
  • the conjugate containing the siRNA provided by the present disclosure can effectively deliver the siRNA active ingredient to the liver and maintain activity in the body for a long time, and can effectively treat and / or prevent pathological conditions and diseases caused by hepatitis B virus infection, Has a good application prospect.
  • FIG. 1 is a PAGE electrophoresis diagram of conjugate 2 after incubation with mouse-derived lysosomal lysate for different times;
  • FIG. 3 is a graph showing changes in normalized serum surface antigen levels over time after subcutaneous administration of a single dose of 3 mg / kg or 1 mg / kg of conjugate 1 (the ordinate is logarithmic);
  • 5 is a graph showing changes in normalized serum HBV DNA levels over time after subcutaneous administration of a single dose of 3 mg / kg or 1 mg / kg of conjugate 1 (the ordinate is logarithmic);
  • Figure 6 shows the inhibitory activity of siRNA1-4 in the psiCHECK system
  • Figure 7 is a PAGE electrophoresis picture of siRNA1-4 and human plasma after different incubation.
  • the HBV gene refers to a gene having a DNA sequence such as Genbank accession number NC_003977.2.
  • the target mRNA refers to the mRNA transcribed from the HBV gene.
  • capital letters C, G, U, A, T represent the base composition of nucleotides; lowercase letter d means that the adjacent nucleotide to the right of the letter d is deoxygenated Ribonucleotides; a lowercase letter m indicates that the adjacent nucleotide to the left of the letter m is a methoxy-modified nucleotide; a lowercase letter f indicates that the adjacent nucleotide to the left of the letter f is fluorinated Modified nucleotides; lowercase letter s indicates that two adjacent nucleotides of the letter s are connected by phosphorothioate groups; uppercase letter P1 indicates that the adjacent nucleotide to the right of the letter P1 is 5 '-Phosphate nucleotide or 5'-phosphate analog modified nucleotide, the letter combination VP indicates that the next nucleotide to the right of the letter combination VP is a vinyl phosphat
  • the terms "complementary” or “reverse complementation” are used interchangeably and have a meaning well known to those skilled in the art, that is, in a double-stranded nucleic acid molecule, the bases of one strand and the other strand The bases on are paired in a complementary manner.
  • the purine base adenine (A) is always paired with the pyrimidine base thymine (T) (or uracil (U) in RNA);
  • the purine base guanine (C) is always paired with the pyrimidine base Cytosine (G) is paired.
  • Each base pair includes a purine and a pyrimidine.
  • mismatch in the art means that in a double-stranded nucleic acid, the bases at corresponding positions are not paired in a complementary form.
  • basically reverse complementation means that there are no more than 3 base mismatches between the two nucleotide sequences involved; basically complete reverse complementation means There is no more than one base mismatch between two nucleotide sequences; completely complementary means that there is no base mismatch between two nucleotide sequences.
  • nucleotide difference between one nucleotide sequence and another nucleotide sequence, which means that the base type of the nucleotide at the same position has changed compared with the latter, for example, in the When the nucleotide base of the latter is A, if the corresponding nucleotide base at the same position of the former is U, C, G, or T, it is determined that the two nucleotide sequences are between the There are nucleotide differences at the positions. In some embodiments, when an abasic nucleotide or an equivalent thereof is used to replace a nucleotide at an original position, it can also be considered that a nucleotide difference has occurred at that position.
  • the fluoro-modified nucleotide refers to a nucleotide in which a hydroxyl group at the 2 ′ position of a ribose group of a nucleotide is replaced by fluorine
  • the non-fluorinated nucleotide refers to a nucleotide A nucleotide or nucleotide analogue formed by the substitution of a hydroxyl group at the 2 ′ position of a ribose group by a non-fluorine group.
  • a nucleotide analogue refers to a nucleotide that can replace a nucleotide in a nucleic acid, but has a structure different from that of adenine ribonucleotide. , Guanine ribonucleotides, cytosine ribonucleotides, uracil ribonucleotides or thymine deoxyribonucleotides. Such as isonucleotides, bridged nucleotides (BNA) or acyclic nucleotides.
  • the methoxy-modified nucleotide refers to a nucleotide formed by replacing the 2′-hydroxy group of a ribosyl group with a methoxy group.
  • modified nucleotide refers to a nucleotide or nucleotide analog formed by substitution of the hydroxyl group at the 2 'position of the ribose group of a nucleotide with another group, or a nucleotide
  • the bases are nucleotides of modified bases.
  • the nucleoside monomer refers to the nucleoside in the siRNA or siRNA conjugate to be prepared according to Types and order of acids, modified or unmodified nucleoside monomers used in phosphoramidite solid-phase synthesis (unmodified or modified RNA phosphoramidites, sometimes RNA phosphoramidites are also called Nucleoside phosphoramidites).
  • Phosphoramidite solid-phase synthesis is a method used in RNA synthesis known to those skilled in the art.
  • the nucleoside monomers used in the present disclosure are all commercially available.
  • conjugate means that two or more chemical moieties each having a specific function are connected to each other in a covalent manner; accordingly, a “conjugate” is It refers to a compound formed by covalent connection between the respective chemical moieties.
  • siRNA conjugate means a compound formed by covalently attaching one or more chemical moieties having a specific function to an siRNA.
  • siRNA conjugate of the present disclosure is also sometimes simply referred to as a "conjugate”.
  • a "conjugated molecule” should be understood as a compound that can be conjugated to an siRNA through a reaction to ultimately form the siRNA conjugate of the present disclosure.
  • the siRNA conjugate or conjugate is a collective term for a first siRNA conjugate and a second siRNA conjugate (described in further detail below).
  • the present disclosure provides an siRNA capable of selectively and effectively reducing the expression of the HBV gene.
  • the siRNA of the present disclosure contains a nucleotide group as a basic structural unit. It is well known to those skilled in the art that the nucleotide group contains a phosphate group, a ribose group, and a base, and details are not described herein again.
  • the siRNA of the present disclosure contains a sense strand and an antisense strand, and each nucleotide of the sense strand and the antisense strand is a modified nucleotide, wherein the sense strand and the antisense strand both include a fluoro-modified nucleotide and Non-fluorinated modified nucleotide, the sense strand comprises nucleotide sequence 1, the antisense strand comprises nucleotide sequence 2, the nucleotide sequence 1 and the nucleotide sequence 2 are at least partially The reverse complementation forms a double-stranded region, wherein the nucleotide sequence 1 and the nucleotide sequence shown in SEQ ID NO: 1 are equal in length and not more than 3 nucleotides apart, and the nucleotides Sequence 2 is the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than 3 nucleotide differences:
  • the nucleotide sequence 1 includes a nucleotide Z A at a position corresponding to Z
  • the nucleotide sequence 2 includes a nucleotide Z ' B at a position corresponding to Z'
  • the Z ' B is antisense The first nucleotide at the 5 'end of the strand
  • the fluoro-modified nucleotides are located in nucleotide sequence 1 and nucleotide sequence 2, no more than 5 fluoro-modified nucleotides in nucleotide sequence 1, and, according to the 5 'end to 3
  • the direction of the 'end, the nucleotides at positions 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified nucleotides; there are not many fluoro-modified nucleotides in the nucleotide sequence 2 Less than 7, and the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence 2 are fluoro-modified nucleotides.
  • positional correspondence means counting from the same end of the nucleotide sequence and being at the same position in the nucleotide sequence.
  • first nucleotide at the 3 ′ end of nucleotide sequence 1 is the nucleotide corresponding to the first nucleotide at the 3 ′ end of SEQ ID NO: 1.
  • nucleotide difference between the nucleotide sequence 1 and SEQ ID NO: 1 and the nucleotide sequence 2 and SEQ ID NO: 2 described above does not significantly reduce the ability of the siRNA to suppress the target gene. Therefore, these include Nucleotide-different siRNAs are also within the scope of this disclosure.
  • nucleotide sequence 1 and the nucleotide sequence shown in SEQ ID NO: 1 are no more than 1 nucleotide difference or no difference, and / or the nucleotide sequence 2 is different from The nucleotide sequence shown in SEQ ID NO: 2 is no more than 1 nucleotide difference or no difference.
  • the nucleotide difference between the nucleotide sequence 2 and the nucleotide sequence shown in SEQ ID NO: 2 includes a difference at the Z ′ B position, and Z ′ B is selected from U, G or C; in some embodiments, the difference of the nucleotide Z 'difference at the position B, Z' is selected from B U, C or G, and Z a is Z 'B complementary to nucleotides.
  • nucleotide sequence 1 and the nucleotide sequence 2 are substantially reverse complementary, substantially completely reverse complementary, or completely reverse complementary; Toward complementation refers to the existence of no more than 3 base mismatches between two nucleotide sequences; said substantially completely reverse complementation refers to the presence of not more than 1 base between two nucleotide sequences Base mismatch; complete reverse complementation means that there is no mismatch between two nucleotide sequences.
  • the sense strand further contains nucleotide sequence 3
  • the antisense strand further contains nucleotide sequence 4
  • the length of the nucleotide sequence 3 and the nucleotide sequence 4 are each 1-4 nucleotides
  • the nucleotide sequence 3 is linked to the 5 'end of the nucleotide sequence 1
  • the nucleotide sequence 4 is linked to the 3' end of the nucleotide sequence 2
  • the nucleotide sequence 3 and the nucleotide sequence 4 are equal in length and are substantially completely reverse complementary or completely reverse complementary; in some specific embodiments, the nucleotide sequence 3 and the core The nucleotide sequence 4 is completely reverse complementary.
  • the length of the sense or antisense strand can independently be 19-23 nucleotides.
  • the siRNA of the present disclosure may have nucleotide sequence 3 and nucleotide sequence 4 selected from the group consisting of nucleotide sequence 3 and nucleotide sequence 4 being completely complementary:
  • Each of the nucleotide sequence 3 and the nucleotide sequence 4 is 1 nucleotide in length, and the base of the nucleotide sequence 3 is G.
  • the length of the double-stranded region may be 20 nucleotides, that is, the ratio of the length of the sense strand and the antisense strand of the siRNA provided in the present disclosure may be 20/20; or,
  • the length of the nucleotide sequence 3 and the nucleotide sequence 4 are 2 nucleotides, and the bases of the nucleotide sequence 3 are U and G in the direction from the 5 ′ end to the 3 ′ end.
  • the length of the double-stranded region may be 21 nucleotides, that is, the ratio of the length of the sense strand and the antisense strand of the siRNA provided in the present disclosure may be 21/21; or,
  • the length of the nucleotide sequence 3 and the nucleotide sequence 4 are 3 nucleotides. According to the direction from the 5 ′ end to the 3 ′ end, the bases of the nucleotide sequence 3 are U, U and G. At this time, the length of the double-stranded region may be 22 nucleotides, that is, the ratio of the length of the sense strand and the antisense strand of the siRNA provided in the present disclosure may be 22/22; or,
  • the length of the nucleotide sequence 3 and the nucleotide sequence 4 are 4 nucleotides. According to the direction from the 5 ′ end to the 3 ′ end, the bases of the nucleotide sequence 3 are A, U, U, and G. At this time, the length of the double-stranded region may be 23 nucleotides, that is, the ratio of the length of the sense strand and the antisense strand of the siRNA provided in the present disclosure may be 23/23.
  • the length of the nucleotide sequence 3 is 2 nucleotides, and the bases of the nucleotide sequence 3 are U and G.
  • the nucleotide sequence 3 and the nucleotide sequence 4 are the same length and complementary to each other. Therefore, the bases of the nucleotide sequence 3 are given, and the bases of the nucleotide sequence 4 are determined. Already.
  • the siRNA of the present disclosure further comprises a nucleotide sequence 5 which is 1 to 3 nucleotides in length and is connected to the 3 ′ end of the antisense strand, thereby constituting The 3 'overhang of the antisense strand.
  • the ratio of the length of the sense strand and the antisense strand of the siRNA provided in the present disclosure can be 19/19, 19/20, 19/21, 19/22, 20/20, 20/21, 20/22, 20 / 23, 21/21, 21/22, 21/23, 21/24, 22/22, 22/23, 22/24, 22/25, 23/23, 23/24, 23/25, or 23/26.
  • the nucleotide sequence 5 is 2 nucleotides in length, and the nucleotide sequence 5 is 2 consecutive thymine deoxyriboses in the direction from the 5 ′ end to the 3 ′ end. Nucleotides, two consecutive uracil ribonucleotides, or two nucleotides complementary to the target mRNA.
  • the ratio of the length of the sense strand and the antisense strand of the siRNA provided by the present disclosure is 19/21 or 21/23.
  • the siRNA provided by the present disclosure has better HBV mRNA silencing activity and / Or Effectively reduce the activity of the surface antigen HBsAg expression.
  • the nucleotide sequence 1 contains a nucleotide sequence shown in SEQ ID NO: 3 or SEQ ID NO: 4 and the nucleotide sequence 2 contains a nucleotide sequence represented by SEQ ID NO: 5, Any nucleotide sequence in the group consisting of the nucleotide sequences shown in SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8:
  • the siRNA of the present disclosure is any one of the following siP1-siP4:
  • Antisense strand 5'-AAUUCGUUGACAUACUUUCUU-3 '(SEQ ID NO: 5),
  • Antisense strand 5'-AAUUCGUUGACAUACUUUCCA-3 '(SEQ ID NO: 6),
  • Antisense strand 5'-UAUUCGUUGACAUACUUUCUU-3 '(SEQ ID NO: 7),
  • Antisense strand 5'-UAUUCGUUGACAUACUUUCCA-3 '(SEQ ID NO: 8),
  • nucleotides at positions 8, 8, 9 or 5, 7, 8, 9 of the nucleotide sequence 1 are fluoro-modified Nucleotides, each of the remaining positions in the sense strand is independently a non-fluorinated nucleotide; in the antisense strand, the second and the second of the nucleotide sequence 2 Nucleotides at positions 6, 14, 16 or 2, 6, 8, 9, 14, and 16 are fluoro-modified nucleotides, and each of the remaining positions in the antisense strand is independently a A non-fluorinated modified nucleotide.
  • a fluoro-modified nucleotide refers to a nucleotide formed by replacing a hydroxyl group at the 2 ′ position of a ribose group of a nucleotide with fluorine, as shown in formula (101), where Base represents a base, Select from C, G, A or U.
  • a non-fluorinated nucleotide refers to a nucleotide or nucleotide analog in which the hydroxyl group at the 2 ′ position of the ribose group of a nucleotide is replaced by a non-fluorine group.
  • each non-fluorinated modified nucleotide is independently selected from nucleotides or nucleotide analogs in which the hydroxyl group at the 2 ′ position of the ribose group of the nucleotide is replaced by a non-fluorine group.
  • Nucleotides in which the hydroxyl group at the 2 ′ position of the ribosyl group is replaced by a non-fluorine group are well known to those skilled in the art. These nucleotides may be selected from, for example, 2′-alkoxy modified nucleotides, 2′- Substituted alkoxy-modified nucleotides, 2'-alkyl-modified nucleotides, 2'-substituted alkyl-modified nucleotides, 2'-amino-modified nucleotides, 2'- One of substituted amino-modified nucleotides, 2'-deoxynucleotides.
  • the 2'-alkoxy-modified nucleotide may be a methoxy-modified nucleotide (2'-OMe), as shown in formula (102); 2'-substituted alkoxy
  • the modified nucleotide can be a 2'-O-methoxyethyl modified nucleotide (2'-MOE), as shown in formula (103); the 2'-amino modified nucleotide (2 ' -NH 2 ) is represented by formula (104).
  • the 2'-deoxynucleotide (DNA) is represented by formula (105).
  • Nucleotide analogs refer to the ability to replace nucleotides in nucleic acids, but differ in structure from adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uracil ribonucleotides or thymine deoxygenates A group of ribonucleotides. Such as isonucleotides, bridged nucleotides (BNA) or acyclic nucleotides.
  • BNA bridged nucleotides
  • the BNA refers to a restricted or inaccessible nucleotide.
  • the BNA may contain a five-, six-, or seven-membered bridged structure with "fixed" C3'-endo sugar shrinkage.
  • the bridge is usually incorporated into the 2'-, 4'- position of the ribose to provide a 2 ', 4'-BNA nucleotide, such as LNA, ENA, cET, BNA, etc., where the LNA is as shown in formula (106) It is shown that ENA is shown in formula (107), and cET and BNA are shown in formula (108).
  • Acyclic nucleotide refers to a type of "open loop" nucleotide formed by the sugar ring of a nucleotide being opened, such as an unlocked nucleic acid (UNA) or a glycerol nucleic acid (GNA), where UNA is represented by formula (109) GNA is shown in formula (110).
  • UNA unlocked nucleic acid
  • GNA glycerol nucleic acid
  • R is selected from H, OH, or alkoxy (O-alkyl).
  • Isonucleotide refers to a compound formed by changing the position of a base on a ribose ring in a nucleotide.
  • a base is formed by moving a base from a 1'-position to a 2'- or 3'-position of a ribose ring.
  • the compound is represented by formula (111) or formula (112).
  • Base represents a base such as A, U, G, C, or T; R is selected from H, OH, F, or a non-fluorine group as described above.
  • the nucleotide analog is selected from one of an isonucleotide, LNA, ENA, cET, UNA, and GNA.
  • each non-fluoro-modified nucleotide is a methoxy-modified nucleotide, and above and below, the methoxy-modified nucleotide refers to the 2 'of the ribosyl group -A nucleotide formed by substitution of a hydroxyl group with a methoxy group.
  • the siRNA of the present disclosure can resist nuclease cleavage in the blood, thereby increasing the blood stability of the nucleic acid, so that the nucleic acid has a stronger resistance to nuclease hydrolysis, while maintaining a high HBV gene inhibitory activity.
  • the siRNA described in the present disclosure achieves a high balance of stability in plasma and gene silencing efficiency in animal experiments, and some also have the advantages of being simpler and lower in cost. Here are some examples.
  • the 7th, 8th, 9th or 5th, 7th, 8th, and 9th positions of the nucleotide sequence 1 The nucleotide is a fluoro-modified nucleotide, and the rest of the nucleotides in the sense strand are methoxy-modified nucleotides; in the antisense strand, the first nucleotide of the nucleotide sequence 2
  • the nucleotides at positions 2, 6, 14, 16 or at positions 2, 6, 8, 9, 14, and 16 are fluoro-modified nucleotides, and the nucleotides at the remaining positions in the antisense strand are methoxy Base modified nucleotides.
  • the nucleotides at positions 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified nucleosides Acid, the nucleotides at the remaining positions in the sense strand are methoxy-modified nucleotides; and in the antisense strand, positions 2, 6, 14, and 16 of the nucleotide sequence 2
  • the nucleotides are fluoro-modified nucleotides, and the nucleotides at other positions in the antisense strand are methoxy-modified nucleotides; or,
  • the nucleotides at positions 5, 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified Nucleotides, the rest of the nucleotides in the sense strand are methoxy modified nucleotides; and in the antisense strand, the second, sixth, eighth, The nucleotides at positions 9, 14, and 16 are fluoro-modified nucleotides, and the nucleotides at other positions in the antisense strand are methoxy-modified nucleotides; or,
  • the nucleotides at positions 5, 7, 8, and 9 of the nucleotide sequence 1 are fluoro-modified Nucleotides, the rest of the nucleotides in the sense strand are methoxy-modified nucleotides; and, in the antisense strand, the 2nd, 6th, 14th, and 2nd nucleotides of the nucleotide sequence 2
  • the nucleotide at position 16 is a fluoro-modified nucleotide, and the nucleotides at other positions in the antisense strand are methoxy-modified nucleotides.
  • the siRNA of the present disclosure is an siRNA shown in any one of Table 1A.
  • the siRNA of the present disclosure further contains other modified nucleotide groups, and the modified nucleotide groups do not cause the siRNA to significantly reduce or lose the function of inhibiting HBV gene expression.
  • the modified nucleotide group is a ribose group and an optional phosphate group modified nucleotide group, but is not limited thereto.
  • At least one of the phosphate groups in the phosphate-sugar backbone of at least one single chain in the sense chain and the antisense chain is a phosphate group having a modifying group.
  • the phosphate group having a modifying group is a thiophosphate group formed by replacing at least one oxygen atom in a phosphodiester bond in the phosphate group with a sulfur atom, and may be a sulfur group represented by formula (1).
  • Phosphorothioate structure replacing a non-bridged oxygen atom in a phosphodiester bond with a sulfur atom, and replacing a phosphodiester bond with a phosphorothioate bond, that is, the connection between two nucleotides is phosphorothioate Ester linkage.
  • This modification can stabilize the structure of siRNA and maintain the high specificity and affinity of base pairing.
  • At least one of the group consisting of linkages between the following nucleotides is a phosphorothioate linkage:
  • the siRNA of the present disclosure is an siRNA shown in any one of Table 1B.
  • the 5 'terminal nucleotide of the antisense strand sequence of the siRNA molecule is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide.
  • a 5'-phosphate nucleotide has a structure represented by formula (2):
  • R represents a group selected from the group consisting of H, OH, F, and methoxy
  • Base represents a base selected from A, U, C, G, or T.
  • the 5'-phosphate analog-modified nucleotide is a nucleotide containing an E-vinylphosphonate (E-VP) shown in formula (3), or a formula (5 Phosphorothioate-containing nucleotides shown in).
  • E-VP E-vinylphosphonate
  • the siRNA of the present disclosure is an siRNA shown in any one of Table 1C or Table 1D.
  • siRNAs of the present disclosure can significantly improve their stability in plasma and lysosomes, while also exhibiting and unexpectedly HBV mRNA Silencing activity and excellent HBsAg inhibition.
  • siRNA described in the present disclosure can be obtained by conventional siRNA preparation methods in the art (such as solid-phase synthesis and liquid-phase synthesis methods). Among them, solid-phase synthesis already has commercial customized services.
  • a method for preparing a modified nucleotide monomer by introducing a modified nucleotide group into the siRNA described in the present disclosure by using a nucleotide monomer having a corresponding modification and a modified nucleotide group Methods for the introduction of siRNAs are also well known to those skilled in the art.
  • the present disclosure provides a pharmaceutical composition containing the siRNA as described above as an active ingredient and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier may be a carrier conventionally used in the field of siRNA administration, such as, but not limited to, magnetic nanoparticles (such as Fe 3 O 4 or Fe 2 O 3 based nanoparticles), carbon nanotubes ( carbon nanotubes), mesoporous silicon, calcium phosphate nanoparticles, polyethylenimine (PEI), polyamidoamine (PAMAM) dendrimer, polylysine Acid (poly (L-lysine), PLL), chitosan, chitosan, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), poly D Poly (D & L-lactic / glycolic acid) copolymer (PLGA), poly (2-aminoethyl ethylene phosphate) (PPEEA), and poly (L-lactic acid) One or more of poly (2-dimethylaminoethyl methacrylate) (PDMAEMA) and their derivatives.
  • magnetic nanoparticles such as Fe
  • the content of the siRNA and the pharmaceutically acceptable carrier is not particularly required in the pharmaceutical composition; in some embodiments, the weight ratio of the siRNA to the pharmaceutically acceptable carrier may be 1 :( 1-500); In some specific embodiments, the weight ratio is 1: (1-50).
  • the pharmaceutical composition may further include other pharmaceutically acceptable excipients, which may be one or more of various formulations or compounds conventionally used in the art.
  • the pharmaceutically acceptable other excipients may include at least one of a pH buffer, a protective agent, and an osmotic pressure adjusting agent.
  • the pH buffer solution may be a trimethylolaminomethane hydrochloride buffer solution having a pH value of 7.5-8.5 and / or a phosphate buffer solution having a pH value of 5.5-8.5. Salt buffer.
  • the protective agent may be at least one of inositol, sorbitol, sucrose, trehalose, mannose, maltose, lactose and glucosamine. Based on the total weight of the pharmaceutical composition, the content of the protective agent may be 0.01-30% by weight.
  • the osmotic pressure adjusting agent may be sodium chloride and / or potassium chloride.
  • the content of the osmotic pressure adjusting agent is such that the osmotic pressure of the pharmaceutical composition is 200-700 milliosmoles / kg. According to the required osmotic pressure, those skilled in the art can easily determine the content of the osmotic pressure regulator.
  • the pharmaceutical composition may be a liquid preparation, such as an injection solution; it may also be a lyophilized powder injection, which is mixed with a liquid auxiliary material during administration to be formulated into a liquid preparation.
  • the liquid preparation may be, but is not limited to, subcutaneous, intramuscular or intravenous administration, and may be, but is not limited to, administration to the lungs by spray, or administration to other organ tissues (such as the liver) by spray.
  • the pharmaceutical composition is for intravenous administration.
  • the pharmaceutical composition may be in the form of a liposome formulation.
  • the pharmaceutically acceptable carrier used in the liposome formulation comprises an amine-containing transfection compound (hereinafter also referred to as an organic amine), a helper lipid, and / or PEGylation Lipid.
  • the organic amine, helper lipid, and PEGylated lipid may be selected from amine-containing transfection compounds described in CN103380113A (which is incorporated herein by reference in its entirety) or a pharmaceutically acceptable compound thereof, respectively.
  • the organic amine may be a compound represented by formula (201) or a pharmaceutically acceptable salt thereof described in CN103380113A:
  • X 101 and X 102 are each independently O, S, NA or CA, where A is hydrogen or a C 1 -C 20 hydrocarbon chain;
  • R 101 , R 102 , R 103 , R 104 , R 105 , R 106 and R 107 are each independently hydrogen, cyclic or acyclic, substituted or unsubstituted, branched or straight chain aliphatic group Group, cyclic or acyclic, substituted or unsubstituted, branched or straight chain heteroaliphatic group, substituted or unsubstituted, branched or straight chain acyl, substituted or unsubstituted Substituted, branched or linear aryl, substituted or unsubstituted, branched or linear heteroaryl;
  • x is an integer from 1-10;
  • n is an integer of 1-3, m is an integer of 0-20, and p is 0 or 1; and wherein, when m and p are both 0, R 102 is hydrogen;
  • R 103 and nitrogen in formula (201) form a structure as shown in formula (202) or formula (203):
  • g, e, and f are each independently an integer of 1-6, "HCC” represents a hydrocarbon chain, and each * N represents a nitrogen atom shown in Formula (201).
  • R 103 is a polyamine. In other embodiments, R 103 is a ketal. In some embodiments, each of R 101 and R 102 in formula (201) is independently any substituted or unsubstituted, branched or straight chain alkyl or alkenyl, said alkane A radical or alkenyl has 3 to about 20 carbon atoms, such as 8 to about 18 carbon atoms, and 0 to 4 double bonds, such as 0 to 2 double bonds.
  • R 103 may be any one of the following formulae (204)-(213):
  • each "HCC” represents a hydrocarbon chain, and each * shows a possible connection point between R 103 and the nitrogen atom in formula (201), where at any * position Each H of can be replaced to achieve a connection to the nitrogen atom in formula (201).
  • the compound represented by formula (201) can be prepared according to the description in CN103380113A.
  • the organic amine is an organic amine represented by formula (214) and / or an organic amine represented by formula (215):
  • the auxiliary lipid is cholesterol, an analog of cholesterol, and / or a derivative of cholesterol;
  • the PEGylated lipid is 1,2-dipalmitamide-sn-glycerol-3-phosphatidylethanolamine-N- [methoxy (polyethylene glycol)]-2000.
  • the molar ratio between the organic amine, the auxiliary lipid, and the PEGylated lipid is (19.7-80): (19.7-80) ) :( 0.3-50), for example, it can be (50-70) :( 20-40) :( 3-20).
  • the particles of the pharmaceutical composition formed by the siRNA of the present disclosure and the above-mentioned amine-containing transfection reagent have an average diameter of about 30 nm to about 200 nm, usually about 40 nm to about 135 nm, and more typically, the liposome
  • the average diameter of the particles is about 50 nm to about 120 nm, about 50 nm to about 100 nm, about 60 nm to about 90 nm, or about 70 nm to about 90 nm.
  • the average diameter of the liposome particles is about 30, 40, 50, 60, 70 , 75, 80, 85, 90, 100, 110, 120, 130, 140, 150 or 160 nm.
  • the weight of the siRNA and all lipids is from about 1: 1 to about 1:50, from about 1: 1 to about 1:30, from about 1: 3 to about 1:20, from about 1: 4 to about 1: 18.From about 1: 5 to about 1:17, from about 1: 5 to about 1:15, from about 1: 5 to about 1:12, from about 1: 6 to about 1:12 or from about 1: In the range of 6 to about 1:10, for example, the weight ratio of the siRNA of the present disclosure to all lipids is about 1: 5, 1: 6, 1: 7, 1: 8, 1: 9, 1:10, 1 : 11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, or 1:18.
  • the components of the pharmaceutical composition may exist independently when sold, and may exist in the form of a liquid formulation when used.
  • the pharmaceutical composition formed by the siRNA provided by the present disclosure and the above-mentioned pharmaceutically acceptable carrier can be prepared according to various known methods, except that the siRNA provided by the present disclosure can be used instead of the existing siRNA; In a specific embodiment, it can be prepared as follows:
  • the alcohol is selected from pharmaceutically acceptable alcohols, such as alcohols that are liquid near room temperature, for example, ethanol, propylene glycol, benzyl alcohol, glycerol, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400 One or more of them may be, for example, ethanol.
  • the siRNA provided in the present disclosure is dissolved in a buffered saline solution to obtain an siRNA aqueous solution.
  • concentration of the buffered saline solution is 0.05-0.5M, for example, it can be 0.1-0.2M.
  • the pH of the buffered saline solution can be adjusted to 4.0-5.5, for example, it can be 5.0-5.2.
  • the amount of buffered saline solution can make the concentration of siRNA not exceed 0.6mg. / mL, for example, may be 0.2-0.4 mg / mL.
  • the buffer salt is selected from one or more of soluble acetate and soluble citrate, and may be, for example, sodium acetate and / or potassium acetate.
  • the lipid solution and the siRNA aqueous solution are mixed, and the mixed product is incubated at 40-60 ° C. for at least 2 minutes, for example, it can be 5-30 minutes to obtain an incubated liposome preparation.
  • the volume ratio of the lipid solution and the siRNA aqueous solution is 1: (2-5), and may be 1: 4, for example.
  • the incubated liposome preparation is concentrated or diluted, impurities are removed, and bacteria are sterilized to obtain the pharmaceutical composition provided by the present disclosure.
  • the physical and chemical parameters are pH 6.5-8, the encapsulation efficiency is not less than 80%, and the particle size is 40-200nm, polydispersity index is not higher than 0.30, osmotic pressure is 250-400mOsm / kg; for example, the physical and chemical parameters can be pH 7.2-7.6, encapsulation rate is not less than 90%, particle size is 60-100nm, and more The dispersion index is not higher than 0.20, and the osmotic pressure is 300-400mOsm / kg.
  • the concentration or dilution may be performed before, after, or at the same time as removing impurities.
  • Various methods can be used to remove impurities.
  • a phase-cut flow system, a hollow fiber column, and ultrafiltration at 100 KDa can be used.
  • the ultrafiltration exchange solution is pH 7.4 phosphate buffered saline (PBS).
  • PBS pH 7.4 phosphate buffered saline
  • sterilization for example, sterilization can be filtered on a 0.22 ⁇ m filter.
  • the present disclosure provides an siRNA conjugate comprising the above-mentioned siRNA provided by the present disclosure and a ligand conjugated to the siRNA.
  • siRNA conjugates are also referred to as the first siRNA conjugates.
  • the type and connection mode of the ligand are well known to those skilled in the art, and its role is generally to bind to a specific receptor on the surface of the target cell, and to mediate the delivery of the siRNA linked to the ligand to the target cell.
  • the ligand conjugated to the siRNA is a pharmaceutically acceptable conjugation group.
  • the conjugated group comprises a pharmaceutically acceptable targeting molecule and an optional linker.
  • the siRNA molecule may be non-covalently or covalently conjugated to the conjugate group, for example, may be covalently conjugated to the conjugate group.
  • the conjugation site of the siRNA and the conjugation group can be at the 3 'end or 5' end of the positive strand of the siRNA, or at the 5 'end of the antisense strand, or in the internal sequence of the siRNA. In some specific embodiments, the conjugation site of the siRNA with a conjugate group is at the 3 ′ end of the positive strand of the siRNA.
  • the conjugate group may be linked to a phosphate group of a nucleotide, a 2′-hydroxyl group or a base, and may also be linked to a 3′-hydroxyl group.
  • the 2'-5 'phosphodiester bond is used for the connection.
  • the conjugate group is usually attached to a phosphate group of a nucleotide; when the conjugate group is attached to an internal sequence of the siRNA, the conjugate group Usually linked to a ribose ring or base.
  • connection methods please refer to the literature: Muthiah, Manoharan, et.al.
  • the siRNA and the conjugate group can be connected by acid-labile or reducible chemical bonds. Under the acidic environment of the cell endosome, these chemical bonds can be degraded, thereby making the siRNA into a free state.
  • the conjugation group can be connected to the sense strand of the siRNA, thereby minimizing the effect of conjugation on siRNA activity.
  • the pharmaceutically acceptable targeting group may be a targeting molecule conventionally used in the field of siRNA administration, such as, but not limited to, one or more of the following targeting molecules or derivatives thereof: lipophilic molecules, such as cholesterol , Bile acids, vitamins (such as vitamin E), lipid molecules with different chain lengths; polymers, such as polyethylene glycol; polypeptides, such as permeant peptides; aptamers; antibodies; quantum dots; sugars, such as lactose, Polylactose, mannose, galactose, N-acetylgalactosamine (GalNAc); folate; or receptor ligands expressed by liver parenchymal cells, such as asialoglycoprotein, asialosaccharide residues, lipids Proteins (such as high density lipoprotein, low density lipoprotein, etc.), glucagon, neurotransmitters (such as adrenaline), growth factors, transferrin, and the like.
  • lipophilic molecules such as cholesterol , Bile acids, vitamins (
  • the pharmaceutically acceptable targeting group may be selected from one or more of the following molecules: asialoglycoproteins, such as asialoseroucomoid (ASOR) ; Asialoglycoprotein receptor (ASGPR) ligand.
  • ASOR asialoseroucomoid
  • ASGPR Asialoglycoprotein receptor
  • the pharmaceutically acceptable targeting group is a ligand of an asialoglycoprotein receptor, and the ligand may be selected from the group consisting of D-mannanose, L-mannanose, D-arabinose, D-xyluranose, L-xyluranose, D-glucose, L-glucose, D-galactose, L-galactose, ⁇ -D-furanmannose, ⁇ -D-furanmannose , ⁇ -D-furanmannose , ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-fructofuranose, ⁇ -D-fructofuranose
  • the pharmaceutically acceptable targeting group may be galactose or N-acetylgalactosamine, wherein the galactose or N-acetylgalactosamine molecule may be monovalent, divalent, trivalent Price, four price.
  • the monovalent, divalent, trivalent, and tetravalent described herein refer to the formation of siRNA conjugates of siRNA molecules with conjugated groups containing galactose or N-acetylgalactosamine molecules as targeting groups, respectively.
  • the molar ratio of the siRNA molecule to the galactose or N-acetylgalactosamine molecule in the first siRNA conjugate is 1: 1, 1: 2, 1: 3, and 1: 4.
  • the pharmaceutically acceptable targeting group is N-acetylgalactosamine.
  • the siRNA described in the present disclosure when the siRNA described in the present disclosure is conjugated to a N-acetylgalactosamine-containing conjugate molecule, the N-acetylgalactosamine molecule is trivalent or tetravalent. In some specific embodiments, when the siRNA described in the present disclosure is conjugated to a N-acetylgalactosamine-containing conjugate molecule, the N-acetylgalactosamine molecule is trivalent.
  • the conjugate molecule can be connected to the siRNA molecule via a suitable linker, and those skilled in the art can select a suitable linker according to the specific type of the targeting molecule.
  • a suitable linker may be a structure represented by formula (301):
  • k is an integer from 1-3;
  • L A is a chain-like moiety including an amide bond having a structure as shown in formula (302), and each of the L A is in an ether bond phase with one of the targeting group and the L C moiety at its two ends, respectively.
  • L B having the formula (303) comprises a pyrrolidine N- acyl chain portion shown structure, the linear portion having a carbonyl group at one end thereof and connected with the L C moiety through an amide bond, at the other end Has an oxygen group and is connected to the siRNA through a phosphate bond:
  • the structure of the siRNA conjugate formed by the N-acetylgalactosamine molecule and the siRNA molecule is shown by the following formula (304):
  • the double helix structure represents siRNA.
  • the conjugation site between the siRNA and the conjugate molecule can be at the 3 'end or 5' end of the siRNA sense strand, or at the 5 'end of the antisense strand, or in the internal sequence of the siRNA.
  • the 3 'end of the sense strand of the siRNA according to the present disclosure is passed through a linker- (L A ) 3 trimethylolaminomethane-L B -and three N-acetylgalactosamine (GalNAc) molecules Covalent conjugation to obtain an siRNA conjugate with a molar ratio of siRNA molecule to GalNAc molecule of 1: 3, which can also be referred to as (GalNAc) 3 -siRNA, and its structure is shown by the following formula (305):
  • double helix structure represents the siRNA
  • the linker is connected to the 3 'end of the sense strand of the siRNA.
  • a suitable linker may have a structure as shown in formula (306):
  • l is an integer from 0 to 3;
  • # Indicates a site on the linker connected to the siRNA through a phosphate bond.
  • the siRNA conjugate has a structure as shown in formula (307):
  • double helix structure represents the siRNA
  • the linker is connected to the 3 'end of the sense strand of the siRNA.
  • conjugated molecules can be synthesized by methods that have been described in detail in the prior art.
  • preparation of various conjugated molecules is described in detail in WO2015006740A2.
  • WO2014025805A1 also describes a method for preparing a conjugated molecule of formula (305).
  • siRNA of the present disclosure can be conjugated to the above-mentioned conjugated molecules in a manner well known to those skilled in the art to obtain the first siRNA conjugate of the present disclosure.
  • the present disclosure provides another siRNA conjugate (hereinafter, also referred to as a second siRNA conjugate, and the terminology is used only for distinguishing from the first siRNA conjugate described above to facilitate The description does not mean that there is any inherent mutually exclusive difference in scope or meaning between the two.)
  • the siRNA conjugate has the structure shown in formula (401):
  • n1 is an integer selected from 1-3, and n3 is an integer selected from 0-4;
  • n1, m2 and m3 are independently an integer selected from 2-10;
  • R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are each independently one of H, methyl or ethyl;
  • R 3 is a group of the structure shown by Formula A59:
  • E 1 is OH, SH or BH 2
  • Nu is the above-mentioned siRNA provided by the present disclosure
  • R 2 is an arbitrary group capable of connecting with N on the nitrogen-containing skeleton and with A59;
  • Each L 1 is independently selected from a combination of one or more of the groups of the formula A1-A26:
  • R ' is C 1 -C 10 alkyl
  • Ra is selected from one of the groups of formula A27-A45:
  • Rb is C 1 -C 10 alkyl
  • Each M 1 is independently selected from one of ligands having an affinity for the asialoglycoprotein receptor (ASGP-R) on the surface of mammalian liver cells.
  • ASGP-R asialoglycoprotein receptor
  • n1 may be selected from an integer of 1-3, and n3 may be selected from an integer of 0-4, ensuring that the number of M 1 ligands in the conjugate is at least 2; in some embodiments, n1 + n3 ⁇ 2, so that the number of M 1 ligands is at least 3, which makes it easier for M 1 ligands to bind to the asialoglycoprotein receptor on the liver surface, thereby facilitating the endocytosis of the conjugate Into the cell.
  • m1, m2 and m3 are independently integers selected from 2-10, can make the spatial position between the plurality of M 1 M 1 for ligand and ligand hepatic asialoglycoprotein receptor surface
  • R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are each independently one of H, methyl or ethyl, the suffix provided by the present disclosure will not be changed.
  • the properties of the compounds can achieve the purpose of the present disclosure.
  • R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are all H.
  • R 2 was chosen to achieve the connection between N and A59 on the nitrogen-containing backbone.
  • nitrogen-containing skeleton refers to a chain structure in which carbon atoms to which R 10 , R 11 , R 12 , R 13 , R 14, and R 15 are connected and N are connected to each other. Therefore, R 2 may be any linking group capable of linking the A59 group to N on the nitrogen-containing skeleton in an appropriate manner.
  • the R 2 group needs to contain both a linking site connected to N on the nitrogen-containing backbone and a Connection site for the P phase in R 3 .
  • R 2 can be B5, B6, B5 'or B6':
  • q 2 may be an integer from 1 to 10. In order to simplify the conjugate provided by the present disclosure, in some embodiments, q 2 is an integer from 1-5.
  • E 1 is OH or SH.
  • L 1 The role of L 1 is to link the M 1 ligand to N on the nitrogen-containing backbone, and to provide liver targeting function for the second siRNA conjugate of the present disclosure.
  • L 1 is selected from one of the groups of formula A1-A26 When combining one or more types of connections, all of the above objectives can be achieved.
  • L 1 is selected from A1, A4, A5, A6 , A8, A10, A11 and A13 are one kind or more connection combination; in some embodiments, L 1 is selected from A1, A4, A8, A10 and A11 are connected to at least two compositions; in some embodiments In the formula, L 1 is selected from a combination of at least two of A1, A8, and A10.
  • the length of L 1 may be 3-25 atoms, 3-20 atoms, 4-15 atoms, or 5-12 atoms. Unless otherwise indicated, in the above and below described herein, the length L 1 is the longest chain of atoms refers to the atom on the N atom in L 1 and connected to the backbone nitrogen atom connected to M 1 formed The number of chain-forming atoms on.
  • j1, j2, R ', Ra, Rb are each selected range, but also to achieve the N-linked M 1 and the nitrogen-containing ligand skeleton, and the spatial position between M 1 is more suitable ligand
  • the M 1 ligand binds to the asialoglycoprotein receptor on the liver surface. Therefore, in some embodiments of the present disclosure, j1 is an integer of 2-10, and in one embodiment, j1 is an integer of 3-5. j2 is an integer of 2-10, and in one embodiment, j2 is an integer of 3-5.
  • R ' is C 1 -C 4 alkyl group, in one embodiment, R' is a methyl, ethyl and isopropyl group of one.
  • Ra is one of A27, A28, A29, A30, and A30. In one embodiment, Ra is A27 or A28.
  • Rb is a C 1 -C 5 alkyl group. In one embodiment, Rb is one of methyl, ethyl, isopropyl, and butyl.
  • M 1 The role of M 1 is to bind to the asialoglycoprotein receptor on the liver surface and promote the endocytosis of the conjugate into the cells. Therefore, it can be selected from any of the asialoglycoprotein receptors on the surface of mammalian liver cells.
  • Ligands (ASGP-R) have affinity ligands, and the types of these ligands are well known to those skilled in the art.
  • each M 1 may be independently selected from a polysaccharide, a modified polysaccharide, a monosaccharide, or a monosaccharide derivative.
  • each M 1 may be independently selected from glucose and its derivatives, mannose and its sugar derivatives, galactose and its derivatives, xylose and its derivatives, ribose and its derivatives, rock One of fucose and its derivatives, lactose and its derivatives, maltose and its derivatives, arabinose and its derivatives, fructose and its derivatives, and sialic acid.
  • each M 1 may be independently selected from D-mannanose, L-mannanose, D-arabinose, D-furanyl xylose, L-furanyl xylose, D-glucose, L-glucose, D-galactose, L-galactose, ⁇ -D-furan mannose, ⁇ -D-furan mannose, ⁇ -D-pyranomannose, ⁇ -D-pyranomannose, ⁇ - D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-fructofurose, ⁇ -D-fructose, ⁇ -D-pyranose Lactose, ⁇ -D-galactopyranosyl, ⁇ -D-galactopyranofuran, ⁇ -D-galactopyranofuran, glucosamine, sialic acid
  • each M 1 is N-acetylgalactosamine (GalNAc). Additional choices of ligands can be found, for example, in the description of CN105378082A, the entire disclosure of which is incorporated herein by reference.
  • the second conjugate of the present disclosure has formulas (403), (404), (405), (406), (407), (408), (409), (410 ), (411), (412), (413), (414), (415), (416), (417), (418), (419), (420), (421), or (422) The structure shown:
  • P in Formula A59 can be ligated to any possible position in the siRNA sequence.
  • P in Formula A59 can be linked to any one of the nucleotides of the siRNA sense or antisense strand; in some embodiments, P is linked to any of the nucleotides of the siRNA sense strand.
  • P in Formula A59 can be linked to the ends of the siRNA sense or antisense strand; in some embodiments, P is linked to the ends of the siRNA sense strand. The end refers to the first 4 nucleotides from the one end of the sense strand or the antisense strand.
  • P in Formula A59 may be linked to the terminus of the siRNA sense or antisense strand; in some embodiments, P is linked to the 3 'terminus of the siRNA sense strand.
  • a separate siRNA antisense strand can be released to block the process of HBV mRNA translation protein , Inhibits hepatitis B virus (HBV) gene expression.
  • HBV hepatitis B virus
  • P in Formula A59 can be linked to any possible position on the nucleotide in the siRNA. In some embodiments, P in Formula A59 can be linked to the 5 'position of a nucleotide, the 2' position of a nucleotide, the 3 'position of a nucleotide, or a base of a nucleotide. In some embodiments, P in Formula A59 can be linked to the 2 ', 3', or 5 'position of a nucleotide in the siRNA by forming a phosphodiester bond.
  • the P in Formula A59 is linked to an oxygen atom formed after dehydrogenation of the 3 ′ hydroxyl group of the 3 ′ terminal nucleotide of the positive strand of the siRNA (in this case, the P atom and the corresponding phosphate group can be Is considered to be attributed to the P atom and phosphate group in the nucleotide), or P in Formula A59 is connected to the nucleotide by replacing the hydrogen in the 2'-hydroxyl group of one nucleotide in the sense strand of the siRNA, Alternatively, P in Formula A59 is linked to the nucleotide by replacing the hydrogen in the 5 ′ hydroxyl group of the 5 ′ terminal nucleotide of the positive strand of the siRNA.
  • the inventors of the present disclosure have unexpectedly discovered that the second siRNA conjugate of the present disclosure, that is, an siRNA conjugate containing the above-mentioned siRNA (for example, the siRNAs shown in Tables 1A-1D above) has significantly improved stability in plasma At the same time, it also showed no significant reduction in HBV mRNA silencing activity and excellent HBsAg and HBV DNA expression inhibition.
  • the second siRNA conjugate of the present disclosure also has a lower off-target effect.
  • the first siRNA conjugate or the second siRNA conjugate of the present disclosure may also be used in combination with other pharmaceutically acceptable excipients.
  • the excipients may be one or more of various preparations or compounds conventionally used in the art. For details, please refer to the above description of the pharmaceutical composition of the present disclosure.
  • the second siRNA conjugate of the present disclosure can be prepared by the following method, which includes the nucleotide types of the positive and antisense strands of the siRNA under the conditions of solid phase synthesis of phosphoramidite, respectively. And sequence, the nucleoside monomers are connected in sequence from 3 'to 5', and the connection of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization; the positive strand of the siRNA and The antisense strand is annealed, wherein the siRNA is the above-mentioned siRNA provided by the present disclosure; and the method further comprises combining the compound represented by formula (321) with a nucleoside in the presence of a coupling reaction condition and a coupling reagent The compound or the nucleotide sequence linked to the solid phase carrier is contacted, so that the compound represented by the formula (321) is linked to the nucleotide sequence through a coupling reaction.
  • the compound represented by formula (321) is
  • R 4 is a group containing any functional group that can be conjugated to the siRNA through a phosphodiester bond through reaction
  • Each S 1 is independently a group formed by the substitution of all active hydroxyl groups in M 1 with a YCOO- group, wherein each Y is independently selected from methyl, trifluoromethyl, difluoromethyl, and monofluoromethyl One of trimethyl, trichloromethyl, dichloromethyl, monochloromethyl, ethyl, n-propyl, isopropyl, phenyl, halophenyl, and alkylphenyl;
  • n1, n3, m1, m2, m3, R 10, R 11, R 12, R 13, R 14, R 15, L 1, M 1 are each as defined previously described and range of choice;
  • R 4 was selected to achieve attachment to N on the nitrogen-containing backbone and to provide a suitable reaction site for the synthesis of the siRNA conjugate of formula (401).
  • R 4 includes a R 2 linking group or a protected R 2 linking group.
  • R 4 contains a functional group capable of forming a structure shown by A59 by reaction with siRNA.
  • R 4 contains group 1, or R 4 contains groups 1 and 2; group 1 contains a functional group that can form a phosphite with a group on a siRNA or nucleoside monomer; a group 2 Contains a functional group that can react with a hydroxyl group or an amino group to form a covalent bond or contains a solid-phase support connected by the covalent bond.
  • the functional group capable of forming a phosphite with a group on an siRNA or a nucleoside monomer is phosphoramidite, a hydroxyl group, or a protected hydroxyl group, and the protective group on the protected hydroxyl group is removed.
  • the hydroxyl group is formed to participate in the reaction;
  • the functional group that can react with the hydroxyl group or the amino group to form a covalent bond is phosphoramidite, carboxylic acid or carboxylate;
  • the solid phase carrier connected by the covalent bond is a solid phase connected by a phosphate bond Carrier, solid phase carrier connected by carboxylic acid ester bond, or solid phase carrier connected by amide bond.
  • the solid phase support is a resin.
  • the group 1 contains a hydroxyl group, -OR k, or a group represented by formula (C3);
  • the group 2 contains formula (C1), (C2), (C3), (C1 ' ) Or (C3 '):
  • q 1 is an integer of 1-4
  • X is O or NH
  • M + is a cation
  • R k is a hydroxyl protecting group
  • Resin represents a solid phase support. Represents a site where a group is covalently attached.
  • the group 1 contains a phosphoramidite functional group, as shown in formula (C3).
  • the phosphoramidite functional group may be related to a hydroxyl group at any position on the nucleotide, such as a 2′-position hydroxyl group or a 3 ′
  • a hydroxy group undergoes a coupling reaction to form a phosphite, and is oxidized or sulfurized to form a phosphodiester bond or a phosphorothioate bond represented by Formula A59, and the conjugate molecule is conjugated to the siRNA.
  • the presence or absence of the group 2 does not affect the obtaining of the siRNA conjugate represented by the formula (401).
  • the compound of formula (321) is reacted with the hydroxyl group on the terminal nucleotide in the nucleotide sequence, and subsequently A phosphodiester linkage or a phosphorothioate linkage is formed during the oxidation or sulfidation process, and the compound of formula (321) is conjugated to the siRNA.
  • the group 1 contains a protected hydroxyl group
  • the group 2 contains a carboxylic acid function, a carboxylate function, or a phosphoramidite function, such as formula (C1), (C2), or (C3)
  • the compound of formula (321) undergoes an esterification reaction or an amidation reaction with a solid support such as a hydroxyl group or an amino group on a resin to form a carboxylic acid. Ester-bonded solid phase carriers or amide-bonded solid phase carriers.
  • the compound of formula (321) undergoes a coupling reaction with a general solid-phase support, such as a hydroxyl group on a resin, and is oxidized to form a solid-phase support linked by a phosphodiester bond.
  • a general solid-phase support such as a hydroxyl group on a resin
  • the nucleoside monomers are sequentially connected according to the phosphoramidite solid-phase synthesis method to obtain the sense or antisense strand of the siRNA to which the conjugate molecule is linked.
  • the group 1 is deprotected, and then coupled with the phosphoramidite group on the nucleoside monomer under the coupling reaction conditions.
  • the group 1 contains a hydroxyl group or a protected hydroxyl group; the group 2 contains a solid phase carrier connected via a carboxylic acid ester bond or a solid phase carrier connected via an amide bond, or a phosphate ester bond
  • the attached solid phase support is shown by formula (C1 ') or (C3').
  • the nucleoside monomers are sequentially connected according to the phosphoramidite solid phase synthesis method to obtain the sense or antisense strand of the siRNA to which the conjugated molecule is linked.
  • the carboxylate functional groups can be expressed as -COO - M +, wherein, M + is a cation, for example selected from metal cation, ammonium cation NH +, organic ammonium cations of one 4.
  • the metal ion is selected from one of alkali metal ions, such as K + or Na + .
  • the organic ammonium ion is an ammonium cation or a quaternary ammonium cation formed by a tertiary amine, such as an ammonium ion or N, N-diamine formed by triethylamine. Ammonium ion formed by isopropylethylamine.
  • the carboxylate is triethylamine carboxylate or N, N-diisopropylethylamine carboxylate.
  • R 4 contains a structure represented by formula (B9), (B10), (B9 '), (B10'), (B11), (B12), (B11 '), or (B12'):
  • q 1 is an integer of 1-4
  • q 2 is an integer of 1-10
  • X is O or NH
  • M + is a cation
  • R k is a hydroxyl protecting group
  • Resin represents a solid support, Represents the site where a group is covalently bonded.
  • q 1 is 1 or 2
  • q 2 is an integer from 1-5.
  • R 4 contains a structure represented by formula (B9) or (B10).
  • R 4 contains a structure represented by formula (B11) or (B12).
  • the selection of the hydroxyl protecting group R k is to replace the hydrogen on the hydroxyl group in R 4 to form a non-reactive group.
  • the protecting group R k can be removed in the subsequent reaction process and the active hydroxyl group can be released again to participate.
  • the kind of the protecting group is well known to those skilled in the art.
  • the protecting group R k may be, for example, Tr (trityl), MMTr (4-methoxytrityl), DMTr ( 4,4'-bismethoxytrityl), TMTr (4,4 ', 4 "-trimethoxytrityl).
  • R k may Is DMTr, which is 4,4'-dimethoxytrityl.
  • the conjugated molecule can be obtained through the above-mentioned group 1 and optional group 2
  • An siRNA conjugate to any possible position of a nucleotide sequence for example, a conjugate molecule is attached to the end of the nucleotide sequence, and a conjugate molecule is attached to the end of the nucleotide sequence.
  • Each S 1 is independently a group formed by replacing all active hydroxyl groups in M 1 with a YCOO- group.
  • an siRNA conjugate is prepared from a compound of formula (321)
  • the active hydroxyl group in M 1 is protected by a YCOO- group, and the protecting group is removed in a subsequent step to obtain a M 1 ligand.
  • each S 1 is independently one of the groups of formulas A46-A54:
  • S 1 is Formula A49 or A50.
  • Each Y is independently selected from methyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, ethyl, n-propyl, isopropyl
  • Y is methyl.
  • the method for preparing the second siRNA conjugate of the present disclosure further includes the following steps: synthesizing another strand of the siRNA (for example, when the above steps synthesize the positive strand of an siRNA with a conjugated molecule connected thereto, The antisense strand of siRNA was synthesized according to the solid phase synthesis method, and vice versa), the sense and antisense strands were separated, and annealing was performed.
  • the solid-phase support linked to the nucleotide sequence and / or the conjugated molecule is cleaved, and at the same time, necessary protecting groups are removed (at this time, each S in the compound of formula (321) 1 group is converted to the corresponding M 1 ligand), and the siRNA sense chain (or antisense strand) and the corresponding antisense strand (or sense strand) linked to the conjugated molecule are obtained.
  • the sense strand and the antisense strand anneal to form a double Strand RNA structure to obtain an siRNA conjugate represented by formula (401).
  • the method for preparing the siRNA conjugate includes the following steps: in the presence of a coupling reaction condition and a coupling reagent, a compound represented by formula (321) and 3 ′ of the sense or antisense strand
  • the first nucleoside monomer at the end is contacted, so that the compound represented by formula (321) is connected to the first nucleotide in the sequence, under the conditions of phosphoramidite solid phase synthesis, according to the desired sense or antisense strand
  • the type and sequence of nucleotides, the nucleoside monomers are sequentially connected in the direction of 3 'to 5' to synthesize the sense or antisense strand of siRNA; wherein (321) the compound R 4 contains a group 1 and a group 2.
  • Group 1 contains a protected hydroxyl group.
  • Group 2 has a compound represented by formula (321) having a structure represented by formula (C1 ') or (C3').
  • the compound of formula (321) is deprotected; the linkage of each nucleoside monomer includes a four-step reaction of deprotection, coupling, capping, oxidation or sulfurization; the sense or antisense strand of the nucleic acid to which the conjugate molecule is linked is obtained; Under the conditions of phosphoramidite solid phase synthesis, according to the type and order of the antisense or sense strand nucleotides, according to the 3 'to 5' formula The nucleoside monomers are connected in sequence to synthesize the antisense or sense strand of the nucleic acid; the connection of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization; the protective group is removed and the solid phase is removed The vector is cut, and the
  • the method for preparing the siRNA conjugate includes the following steps: According to the nucleotide type and sequence of the sense strand or the antisense strand in the double-stranded siRNA, the nucleoside is directed in a 3 ′ to 5 ′ direction The monomers are connected in sequence to synthesize the sense and antisense strands.
  • each nucleoside monomer includes four steps: deprotection, coupling, capping, oxidation or sulfurization, to obtain the sense chain and the Antisense strand on a solid support; in the presence of a coupling reaction condition and a coupling reagent, a compound represented by formula (321) and a sense strand attached to the solid support or an antisense attached to the solid support Chain contact to connect a compound of formula (321) to the sense or antisense chain, wherein the compound of formula (321) is a compound of formula (321) containing R 1 in group R 4 and group 1 is a phosphoramidite group Removing the protection group and cutting it with the solid phase carrier, separating and purifying the siRNA to obtain a sense or antisense strand, respectively, and annealing, wherein a conjugate molecule is connected to the sense or antisense strand of the siRNA.
  • the nucleoside monomer used is selected based on the desired siRNA sequence in the second siRNA conjugate. For example, when the siRNA sequence contains a fluoro- or methoxy-modified nucleotide, the corresponding fluoro- or methoxy-modified nucleoside monomer is used accordingly in the siRNA synthesis. As previously mentioned, these fluoro- or methoxy-modified nucleoside monomers are well known in the art and are readily available commercially.
  • P in Formula A59 is linked to the 3 ′ end of the sense strand in the siRNA, and the method for preparing a second siRNA conjugate of the present disclosure includes:
  • the method of removing the protective group R k in the compound of the formula (321) includes contacting the compound of the formula (321) with a deprotecting agent under deprotection conditions.
  • Deprotection conditions include a temperature of 0-50 ° C, in one embodiment 15-35 ° C, a reaction time of 30-300 seconds, and in one embodiment 50-150 seconds, the deprotection reagent may be selected from trifluoroacetic acid Or more, trichloroacetic acid, dichloroacetic acid, monochloroacetic acid, and in one embodiment dichloroacetic acid.
  • the molar ratio of the deprotection reagent to the compound of formula (321) is 10: 1-1000: 1, and in one embodiment 50: 1-500: 1.
  • any conditions and reagents capable of realizing the above coupling reaction can be used.
  • the same conditions and reagents as the coupling reaction in the solid-phase synthesis method used can be used.
  • the conditions of the coupling reaction include a reaction temperature of 0-50 ° C, and in one embodiment, 15-35 ° C.
  • the molar ratio of the compound of formula (321) to the nucleoside monomer is 1: 1-1: 50, in one embodiment 1: 2-1: 5; the molar ratio of the compound of formula (321) and the coupling reagent is 1 : 1-1: 50, in one embodiment 1: 3-1: 10, the reaction time is 200-3000 seconds, and in one embodiment 500-1500 seconds.
  • the coupling reagent is selected from one or more of 1H-tetrazole, 5-ethylthio 1H-tetrazole, 5-benzylthio 1H-tetrazole, and in one embodiment 5-ethylthio 1H-tetrazole.
  • the coupling reaction may be performed in an organic solvent selected from one or more of anhydrous acetonitrile, anhydrous DMF, and anhydrous dichloromethane, and in one embodiment, anhydrous acetonitrile.
  • the amount of the organic solvent is 3-50 L / mol, and in one embodiment, 5-20 L / mol.
  • step (2) by the method of solid phase synthesis of phosphoramidite nucleic acid, using the nucleoside monomer prepared by the above step and connected to the solid phase carrier through a conjugate molecule to start, and synthesize siRNA in the direction of 3'-5 ' The sense chain S of the conjugate. At this point, the conjugated molecule is attached to the 3 'end of the resulting sense strand.
  • conditions for the solid-phase synthesis described in steps (2) and (3) include nucleoside monomer deprotection conditions, types and amounts of deprotection reagents, coupling reaction conditions, types and amounts of coupling reagents, Conditions, types and amounts of capping reagents, oxidation reaction conditions, types and amounts of oxidation reagents, sulfurization reaction conditions, sulfurization reagents and amounts use various reagents, amounts and conditions conventionally used in the art.
  • the following conditions can be used for the solid-phase synthesis described in steps (2) and (3):
  • the nucleoside monomer deprotection conditions include a temperature of 0-50 ° C, in one embodiment 15-35 ° C, a reaction time of 30-300 seconds, and in one embodiment 50-150 seconds, a deprotection reagent can be selected From one or more of trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, monochloroacetic acid, and in one embodiment dichloroacetic acid.
  • the molar ratio of the deprotection reagent to the 4,4'-dimethoxytrityl protecting group on the solid support is 2: 1-100: 1, and in one embodiment is 3: 1-50: 1.
  • Coupling reaction conditions include a temperature of 0-50 ° C, in one embodiment 15-35 ° C, a molar ratio of a nucleic acid sequence linked to a solid phase support to a nucleoside monomer of 1: 1-1: 50.
  • 1: 5-1: 15; the molar ratio of the nucleic acid sequence and the coupling reagent connected on the solid phase carrier is 1: 1-1: 100, and in one embodiment, 1: 50-1: 80,
  • the reaction time and selection of coupling reagents are the same as described above.
  • the capping reaction conditions include a temperature of 0-50 ° C, in one embodiment 15-35 ° C, a reaction time of 5-500 seconds, and in one embodiment 10-100 seconds.
  • the selection of the capping reagent is the same as described above.
  • the molar ratio of the total amount of the capping reagent to the linked nucleic acid sequence on the solid phase carrier is 1: 100-100: 1, and in one embodiment 1: 10-10: 1.
  • the capping reagent uses an equimolar amount of acetic anhydride and N-methylimidazole
  • the molar ratio of acetic anhydride, N-methylimidazole and the nucleic acid sequence connected to the solid support is 1: 1: 10-10: 10 : 1, in one embodiment 1: 1: 2-2: 2: 1.
  • the oxidation reaction conditions include a temperature of 0-50 ° C, in one embodiment 15-35 ° C, a reaction time of 1-100 seconds, in one embodiment 5-50 seconds, and an oxidation reagent in one embodiment is iodine (In one embodiment, provided as iodine).
  • the molar ratio of the oxidizing reagent to the nucleic acid sequence attached to the solid-phase support in the coupling step is 1: 1-100: 1, and in one embodiment 5: 1-50: 1.
  • the curing reaction conditions include a temperature of 0-50 ° C, in one embodiment 15-35 ° C, a reaction time of 50-2000 seconds, in one embodiment 100-1000 seconds, and a sulfurization reagent in one embodiment is hydrogenation.
  • a sulfurization reagent in one embodiment is hydrogenation.
  • the molar ratio of the sulfurization reagent to the nucleic acid sequence attached to the solid-phase carrier in the coupling step is 10: 1-1000: 1, and in one embodiment, 10: 1-500: 1.
  • the method After ligating all nucleoside monomers and before annealing, the method also includes isolating the sense and antisense strands of the siRNA. Isolation methods are well known to those skilled in the art, and generally include cleavage of the synthesized nucleotide sequence from a solid phase support, removal of protective groups on the base, phosphate group and ligand, purification and desalting .
  • the synthetic nucleotide sequence can be cleaved from the solid phase carrier, and the protective groups on the base, phosphate group and ligand can be removed according to the conventional cleavage and deprotection methods in siRNA synthesis.
  • the obtained solid-phase-supported nucleotide sequence is contacted with concentrated ammonia water; in the process of deprotection, the protective group YCO- of the A46-A54 group is converted into a hydroxyl group, and the S 1 group is converted into the corresponding M 1 group to form a conjugate represented by formula (401).
  • the concentrated ammonia water refers to 25-30% by weight of ammonia water, and the amount of concentrated ammonia water is 0.2ml / ⁇ mol-0.8ml / ⁇ mol compared with the target siRNA sequence.
  • the method further comprises contacting the nucleotide sequence from which the solid phase carrier is removed with triethylamine trihydrofluoride to remove the 2'-TBDMS protection.
  • the obtained target siRNA sequence has a corresponding 2'-hydroxyl corresponding nucleoside.
  • the amount of pure triethylamine trihydrofluoride is 0.4ml / ⁇ mol-1.0ml / ⁇ mol compared with the target siRNA sequence. In this way, a second siRNA conjugate of the present disclosure can be obtained.
  • a preparative ion chromatography purification column can be used to complete the purification of nucleic acids by gradient elution of NaBr or NaCl. After the products are collected and combined, a reversed-phase chromatography purification column can be used for desalination.
  • the non-bridged oxygen atom or sulfur atom in the phosphodiester bond or phosphorothioate bond between the nucleotides is basically bound to the sodium ion
  • the siRNA conjugate is basically in the form of a sodium salt. presence.
  • the well-known ion exchange method can be used to replace the sodium ions with hydrogen ions or other cations to obtain other forms of siRNA conjugates. The cation is described in detail later.
  • nucleic acid purity can be detected by ion exchange chromatography, and molecular weight can be determined by liquid chromatography-mass spectrometry.
  • the method of annealing is also well known to those skilled in the art.
  • the synthesized sense chain (S chain) and antisense chain (AS chain) can be simply mixed in an equimolar ratio in water for injection and heated to 70-95 ° C, followed by cooling at room temperature to form double bonds through hydrogen bonding. Chain structure.
  • S chain sense chain
  • AS chain antisense chain
  • a second siRNA conjugate of the present disclosure can be obtained.
  • a method such as liquid chromatography-mass spectrometry can be used to characterize the synthesized siRNA conjugate through a method such as molecular weight detection to determine the
  • the synthetic siRNA conjugate is a target designed siRNA conjugate, and the sequence of the synthesized siRNA matches the sequence of the siRNA to be synthesized, for example, the sequences listed in the above Tables 1A-1D.
  • the compound represented by the formula (321) can be obtained by the following preparation method: the method comprises combining the compound represented by the formula (313) with a cyclic compound in an organic solvent, under the conditions of an esterification reaction, and in the presence of a base and an ester-forming catalyst. Contact with acid anhydride, ion exchange, and isolation to obtain the compound represented by formula (321):
  • R 6 has a structure represented by formula (A61):
  • R i is an arbitrary group capable of being connected to N on the nitrogen-containing skeleton, to R k O, and having a free hydroxyl group attached thereto, and R k is a hydroxyl protecting group.
  • R 4 contains a group 1 and a group 2, the group 1 contains a hydroxyl protecting group, and the group 2 contains a compound of formula (321) having a structure represented by formula (C1) or (C2) .
  • the esterification reaction conditions include a reaction temperature of 0-100 ° C and a reaction time of 8-48 hours. In one embodiment, the esterification reaction conditions are a reaction temperature of 10-40 ° C and a reaction time of 20-30 hour.
  • the organic solvent is one or more of an epoxy-based solvent, an ether-based solvent, a haloalkane-based solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine.
  • the epoxy-based solvent is dioxane and / or tetrahydrofuran
  • the ether-based solvent is diethyl ether and / or methyl tert-butyl ether
  • the haloalkane-based solvent is dichloromethane, One or more of methyl chloride and 1,2-dichloroethane.
  • the organic solvent is dichloromethane. Relative to the compound represented by the formula (313), the organic solvent is used in an amount of 3-50 L / mol, and in one embodiment, 5-20 L / mol.
  • the cyclic anhydride is one of succinic anhydride, glutaric anhydride, adipic anhydride, or pimelic anhydride, and in one embodiment, succinic anhydride.
  • the molar ratio of the cyclic anhydride to the compound represented by the formula (313) is 1: 1-10: 1, and in one embodiment 2: 1-5: 1.
  • the ester-forming catalyst may be any catalyst that catalyzes the esterification reaction.
  • the catalyst may be 4-dimethylaminopyridine.
  • the molar ratio of the catalyst to the compound represented by formula (313) is 1: 1-10: 1, and in one embodiment 2: 1-5: 1.
  • the base may be any inorganic base, organic base, or a combination thereof.
  • the base may be, for example, a tertiary amine organic base.
  • the tertiary amine organic base is triethylamine or N, N-diisopropylethylamine.
  • the molar ratio of the tertiary amine organic base to the compound represented by formula (313) is 1: 1-20: 1, and in one embodiment is 3: 1-10: 1.
  • the ion exchange is to convert the compound of formula (321) into a desired carboxylic acid or carboxylate form.
  • the method of ion exchange is well known to those skilled in the art, and suitable ion exchange solutions and exchange conditions can be used to obtain the foregoing.
  • the cation is a M + conjugated molecule, which will not be described in detail here.
  • the ion exchange reaction is performed using a triethylamine phosphate solution, and the concentration of the triethylamine phosphate solution is 0.2-0.8M, in one embodiment, 0.4-0.6M, relative to the formula (313) A compound, wherein an amount of the triethylamine phosphate solution is 3-6 L / mol, and in one embodiment, 4-5 L / mol.
  • the compound of formula (321) can be isolated from the reaction mixture using any suitable separation method.
  • the solvent can be removed directly to obtain a crude product of the compound of formula (321), which can be used directly in subsequent reactions.
  • the method for preparing a compound of formula (321) further comprises: under a condensation reaction condition, in an organic solvent, in the presence of a condensing agent and a tertiary amine organic base, a product obtained by the ion exchange reaction Further, it is contacted with a solid-phase support containing an amino group or a hydroxyl group.
  • R 4 contains a group 1 and a group 2
  • the group 1 contains a hydroxyl protecting group
  • the group 2 contains a compound of the formula (321) having a structure represented by the formula (C1 ′).
  • the solid-phase carrier is one of the carriers used in the solid-phase synthesis of siRNA, and some of them are well known to those skilled in the art.
  • the solid phase support may be selected from a solid phase support containing an active hydroxyl or amino functional group, and in one embodiment an amino resin or a hydroxyl resin.
  • the amino or hydroxy resin has the following parameters in one embodiment: a particle size of 100-400 mesh, and a surface amino or hydroxy loading of 0.2-0.5 mmol / g.
  • the usage ratio of the compound represented by the formula (321) to the solid-phase support is 10-400 ⁇ mol / g, and in one embodiment, 50-200 ⁇ mol / g.
  • the organic solvent is one of acetonitrile, epoxy-based solvent, ether-based solvent, haloalkane-based solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine. Or more.
  • the epoxy-based solvent is dioxane and / or tetrahydrofuran
  • the ether-based solvent is diethyl ether and / or methyl tert-butyl ether
  • the haloalkane-based solvent is dichloromethane, One or more of methyl chloride and 1,2-dichloroethane.
  • the organic solvent is acetonitrile. Relative to the compound of formula (321), the amount of the organic solvent is 20-200 L / mol, and in one embodiment, 50-100 L / mol.
  • the condensing agent may be benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate, 3-diethoxyphosphoryl-1,2,3-benzoazole 4 (3H) -one and O-benzotriazole-tetramethylurea hexafluorophosphate, in one embodiment O-benzotriazole-tetramethylurea hexafluorophosphate.
  • the molar ratio of the condensing agent to the compound represented by formula (321) is 1: 1-20: 1, and in one embodiment is 1: 1-5: 1.
  • the tertiary amine organic base is triethylamine and / or N, N-diisopropylethylamine, and in one embodiment N, N-diisopropylethylamine;
  • the molar ratio of the tertiary amine organic base to the compound represented by formula (321) is 1: 1-20: 1, and in one embodiment is 1: 1-5: 1.
  • the method for preparing a compound of formula (321) may further include contacting the obtained condensation product with a capping reagent and an acylation catalyst in an organic solvent under a capping reaction condition to isolate and obtain the formula (321) Compound.
  • the function of the capping reaction is to remove any active reactive functional groups that have not been completely reacted, so as to avoid generating unnecessary by-products in subsequent reactions.
  • the conditions of the cap reaction include a reaction temperature of 0-50 ° C., in one embodiment 15-35 ° C., a reaction time of 1-10 h, and in one embodiment 3-6 h.
  • a capping reagent used in siRNA solid-phase synthesis can be used as the capping reagent.
  • the capping reagent used in siRNA solid-phase synthesis is well known to those skilled in the art.
  • the capping reagent is composed of cap reagent 1 (cap1) and cap reagent 2 (cap2), wherein cap reagent 1 is N-methylmethylimidazole, and in one embodiment N-methylimidazole Pyridine / acetonitrile mixed solution is provided, wherein the volume ratio of pyridine to acetonitrile is from 1:10 to 1: 1, and in one embodiment is 1: 3-1: 1, and the total volume of pyridine to acetonitrile and N-formaldehyde The volume of the imidazole is 1: 1-10: 1, and in one embodiment 3: 1-7: 1.
  • the capping reagent 2 is acetic anhydride, and is provided as an acetonitrile solution of acetic anhydride in one embodiment, wherein the volumes of acetic anhydride and acetonitrile are 1: 1-1: 10, and in one embodiment 1: 2- 1: 6.
  • the ratio of the volume of the pyridine / acetonitrile mixed solution of N-methylimidazole to the mass of the compound of formula (321) is 5ml / g-50ml / g, and in one embodiment 15ml / g- 30ml / g.
  • the ratio of the volume of the acetonitrile solution of acetic anhydride to the mass of the compound of formula (321) is 0.5ml / g-10ml / g, and in one embodiment is 1ml / g-5ml / g.
  • the capping reagent uses an equimolar amount of acetic anhydride and N-methylimidazole.
  • the organic solvent is one of acetonitrile, epoxy-based solvent, ether-based solvent, haloalkane-based solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine. Or more.
  • the organic solvent is acetonitrile.
  • the amount of the organic solvent is 10-50 L / mol, and in one embodiment, 5-30 L / mol.
  • the acylation catalyst may be selected from any catalyst which can be used for ester-forming condensation or amide-forming condensation, such as a basic heterocyclic compound.
  • the acylation catalyst is 4-dimethylaminopyridine.
  • the mass ratio of the catalyst to the compound represented by formula (321) is 0.001: 1-1: 1, and in one embodiment, 0.01: 1-0.1: 1.
  • the compound of formula (321) can be isolated from the reaction mixture using any suitable separation method.
  • the compound of formula (321) can be obtained by washing thoroughly with an organic solvent and filtering to remove unreacted reactants, excess capping reagents, and other impurities.
  • the organic solvent is selected from acetonitrile and dichloromethane. And methanol, in one embodiment acetonitrile.
  • a method for preparing a conjugated molecule represented by formula (321) includes combining the compound represented by formula (313) with phosphorous acid in an organic solvent, under coupling reaction conditions, and in the presence of a coupling reagent.
  • the acid diamine is contacted to isolate a compound represented by the formula (321).
  • R 4 contains a group 1 and a group 2
  • the group 1 contains a hydroxyl protecting group
  • the group 2 contains a compound of the formula (321) having a structure represented by the formula (C3).
  • the coupling reaction conditions include a temperature of 0-50 ° C, for example, 15-35 ° C, and a molar ratio of the compound of formula (313) to phosphorous diamine is 1: 1-1: 50, such as 1: 5-1: 15;
  • the molar ratio of the compound of formula (313) to the coupling reagent is 1: 1-1: 100, such as 1: 50-1: 80;
  • the reaction time is 200-3000 seconds, such as 500-1500 seconds.
  • the phosphorous diamine can be, for example, bis (diisopropylamino) (2-cyanoethoxy) phosphine, which is commercially available or synthesized according to a method known in the art.
  • the coupling reagent is selected from one or more of 1H-tetrazole, 5-ethylthio 1H-tetrazole, 5-benzylthio 1H-tetrazole, for example, 5-ethylthio 1H-tetrazol Azole.
  • the coupling reaction may be performed in an organic solvent selected from one or more of anhydrous acetonitrile, anhydrous DMF, and anhydrous dichloromethane, such as anhydrous acetonitrile. Relative to the compound of formula (313), the organic solvent is used in an amount of 3-50 L / mol, for example, 5-20 L / mol.
  • the hydroxyl group in the compound of the formula (313) reacts with phosphorous diamine to form a phosphoramidite group.
  • the solvent can be removed directly to obtain a crude product of the compound of formula (321), which can be used directly in subsequent reactions.
  • the method for preparing a compound of formula (321) further includes the following steps: under the coupling reaction conditions, in an organic solvent, and in the presence of a coupling reagent, further separating the isolated product with a hydroxyl-containing The solid support is contacted. Subsequently, the compound of formula (321) is isolated through a capping reaction and an oxidation reaction. At this time, a compound of the formula (321) having R 1 containing a group 1 and a group 2, a group 1 containing a hydroxyl protecting group, and a group 2 having a structure represented by the formula (C3 ′) is obtained.
  • the solid-phase carrier is a solid-phase carrier that is well-known in the art and can be used for nucleic acid solid-phase synthesis.
  • the solid-phase carrier may be a commercially available general-purpose solid-phase carrier after deprotection reaction ( (UnyLinker TM 300 Oligonucleotide Synthesis Support, Kinovate Life Sciences, the structure is shown in formula B80):
  • the deprotection conditions include a temperature of 0-50 ° C, such as 15-35 ° C, and a reaction time of 30-300 seconds, such as 50-150 seconds.
  • the deprotection reagent may be selected from one or more of trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, and monochloroacetic acid. In some embodiments, the deprotection reagent is dichloroacetic acid.
  • the molar ratio of the deprotecting reagent to the -DMTr (4,4'-dimethoxytrityl) protecting group on the stationary phase is 2: 1-100: 1, for example, 3: 1-50: 1.
  • Coupling reaction conditions and selection of coupling reagents are as described above. By performing this coupling reaction, the free hydroxyl group formed in the deprotection reaction reacts with the phosphoramidite group to form a phosphite linkage.
  • Capping reaction conditions include a temperature of 0-50 ° C, such as 15-35 ° C, a reaction time of 5-500 seconds, such as 10-100 seconds, and the capping reaction is performed in the presence of a capping reagent.
  • the selection and amount of the capping reagent are as described above.
  • the oxidation reaction conditions include a temperature of 0-50 ° C, for example, 15-35 ° C, a reaction time of 1-100 seconds, for example, 5-50 seconds, and an oxidation reagent, such as iodine (in some embodiments, iodine Provided in the form of water).
  • iodine in some embodiments, iodine Provided in the form of water.
  • the molar ratio of the oxidizing agent to the phosphite group is 1: 1-100: 1, for example, it can be 5: 1-50: 1.
  • R 6 is one of the groups of formula B7 or B8,
  • the compound represented by the formula (313) can be obtained by the following preparation method: in an organic solvent, under the amide-forming reaction conditions, and in the presence of an amide-forming reaction condensing agent and a tertiary amine organic base, The compound represented by) is contacted with the compound represented by formula (A-1) or the compound represented by formula (A-2), and the compound represented by formula (313) is isolated:
  • 13, R 14, R 15 , L 1, S 1, q 2 , and R k are each as defined and selectable range n1, n3, m1, m2, m3, R 10, R 11, R 12, R as Previously mentioned.
  • the amide-forming reaction conditions are a reaction temperature of 0-100 ° C and the reaction time is 1-48 hours. In one embodiment, the amide-forming reaction conditions are a reaction temperature of 10-40 ° C and a reaction time of 2-16 hour.
  • the organic solvent is an alcohol solvent, an epoxy solvent, an ether solvent, a haloalkane solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine.
  • the alcohol solvent is one or more of methanol, ethanol, and propanol in one embodiment, and ethanol in one embodiment.
  • the epoxy-based solvent is dioxane and / or tetrahydrofuran.
  • the ether-based solvent is diethyl ether and / or methyl tert-butyl ether.
  • the halogenated alkane solvent is one or more of methylene chloride, chloroform, and 1,2-dichloroethane.
  • the organic solvent is dichloromethane. Relative to the compound of formula (314), the amount of the organic solvent is 3-50 L / mol, and in one embodiment, 3-20 L / mol.
  • the amide-forming reaction condensing agent is benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate, 3-diethoxyphosphoryl-1,2,3-benzoazole 4 (3H)- Ketone, 4- (4,6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydro Quinoline (EEDQ) or O-benzotriazole-tetramethylurea hexafluorophosphate, in one embodiment 3-diethoxyphosphoryl-1,2,3-benzoazole 4 (3H) -ketone.
  • the molar ratio of the amide-forming reaction condensing agent to the compound represented by formula (314) is 1: 1-10: 1, and in one embodiment is 2.5: 1-5: 1.
  • the tertiary amine organic base is triethylamine or N, N-diisopropylethylamine, and in one embodiment is N, N-diisopropylethylamine.
  • the molar ratio of the tertiary amine organic base to the compound represented by formula (314) is 3: 1-20: 1, and in one embodiment is 5: 1-10: 1.
  • Compounds of formula (A-1) and formula (A-2) can be prepared by any suitable method.
  • R k is a DMTr group
  • a compound of formula (A-1) can be prepared by reacting calcium glycerate with DMTrCl; similarly, 3-amino-1,2-propanediol can be first contacted with a cyclic anhydride, and then Then, it is reacted with DMTrCl to prepare a compound of formula (A-2).
  • the cyclic acid anhydride may be a cyclic acid anhydride having 4-13 carbon atoms, and in one embodiment 4-8.
  • the compound of formula (313) can also be prepared by reacting the compound represented by formula (314) with the cyclic acid anhydride, 3-amino-1,2-propanediol, and DMTrCl in that order. It is easily understood by those skilled in the art that these modifications will not affect the structure and function of the compound of formula (313), and these modifications are easily implemented by those skilled in the art on the basis of the above method.
  • the compound of formula (313) can be isolated from the reaction mixture using any suitable separation method.
  • the solvent can be removed directly to obtain a crude product of the compound of formula (313), which can be used directly in subsequent reactions.
  • the compound represented by formula (314) can be obtained by the following preparation method: the method comprises contacting the compound represented by formula (315) with a halogenated acetic acid in an organic solvent under deprotection reaction conditions to obtain the formula (314) ) Compounds shown:
  • R 7 is selected from the group represented by formula (330), (331), (332) or (333). In one embodiment, the structure of R 7 is represented by formula (330):
  • the haloacetic acid is selected from one or more of dichloroacetic acid, trichloroacetic acid, monochloroacetic acid, and trifluoroacetic acid, and in one embodiment is dichloroacetic acid.
  • the deprotection reaction conditions include a reaction temperature of 0-100 ° C, a reaction time of 0.1-24 hours, and in one embodiment, a reaction temperature of 10-40 ° C, and a reaction time of 0.5-16 hours.
  • the organic solvent is one or more of an epoxy-based solvent, an ether-based solvent, a haloalkane-based solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine.
  • the epoxy-based solvent is dioxane and / or tetrahydrofuran in one embodiment
  • the ether-based solvent is diethyl ether and / or methyl tert-butyl ether in one embodiment
  • the haloalkane-based solvent is In an embodiment, it is one or more of dichloromethane, chloroform, and 1,2-dichloroethane.
  • the organic solvent is dichloromethane. Relative to the compound of formula (315), the amount of the organic solvent is 3-50 L / mol, and in one embodiment, 5-20 L / mol.
  • the molar ratio of the halogenated acetic acid to the compound represented by the formula (315) is 5: 1 to 100: 1, and in one embodiment, 10: 1 to 50: 1.
  • the compound of formula (314) can be isolated from the reaction mixture using any suitable separation method.
  • the solvent can be removed directly to obtain a crude product of the compound of formula (314), which can be used directly in subsequent reactions.
  • the compound represented by the formula (315) can be obtained by the following preparation method: the method comprises: in an organic solvent, in the presence of an amide-forming reaction condensing agent and a tertiary amine organic base; The compound shown in the formula (316) is contacted, and the compound represented by the formula (315) is isolated:
  • n1, n3, m1, m2 , m3, R 7, R 10, R 11, R 12, R 13, R 14, R 15, L 1, S 1 and are each as defined previously described selectable range .
  • the compound of the formula (316) can be, for example, a compound disclosed in J. Am. Chem. Soc. 2014, 136, 16958-16961, or the compound of the formula (316) can be prepared by a person skilled in the art through various methods. Certain compounds of formula (316) were prepared with reference to the method disclosed in Example 1 of US8106022B2, the entire contents of which are incorporated herein by reference in their entirety.
  • the condensation reaction conditions include a reaction temperature of 0-100 ° C, a reaction time of 0.1-24 hours, and in one embodiment, a reaction temperature of 10-40 ° C, and a reaction time of 0.5-16 hours.
  • the molar ratio of the compound represented by the formula (316) to the compound represented by the formula (317) is 2: 1-10: 1, and in one embodiment is 2.5: 1-5: 1.
  • the organic solvent is one of acetonitrile, epoxy-based solvent, ether-based solvent, haloalkane-based solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine.
  • the epoxy-based solvent is dioxane and / or tetrahydrofuran in one embodiment
  • the ether-based solvent is diethyl ether and / or methyl tert-butyl ether in one embodiment
  • the solvent-like solvent is one or more of dichloromethane, chloroform, and 1,2-dichloroethane in one embodiment.
  • the organic solvent is acetonitrile. Relative to the compound of formula (317), the amount of the organic solvent is 3-50 L / mol, and in one embodiment, 5-20 L / mol.
  • the amide-forming reaction condensing agent is benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate, 3-diethoxyphosphoryl-1,2,3-benzoazole 4 (3H)- Ketone (DEPBT), O-benzotriazol-tetramethylurea hexafluorophosphate or 4- (4,6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride , In one embodiment, 4- (4,6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride.
  • the molar ratio of the amide-forming reaction condensing agent to the compound represented by formula (317) is 2: 1-10: 1, and in one embodiment is 2.5: 1-5: 1.
  • the tertiary amine organic base is N-methylmorpholine, triethylamine or N, N-diisopropylethylamine, in one embodiment N-methylmorpholine; the tertiary amines
  • the molar ratio of the organic base to the compound represented by the formula (317) is 3: 1-20: 1, and in one embodiment is 5: 1-10: 1.
  • the compound of formula (315) can be separated from the reaction mixture using any suitable separation method.
  • the solvent can be removed by evaporation and then the compound of formula (315) can be separated by chromatography.
  • the solvent can be removed directly to obtain a crude product of the compound of formula (315), which can be used directly in subsequent reactions.
  • the compound of formula (317) is reacted with a sufficient amount of one compound of formula (316) to generate the desired compound of formula (315) at one time. At this time, the respective S 1 -L 1 moieties are the same as each other.
  • the compound of formula (317) can be reacted batchwise with different compounds of formula (316), that is, compounds of formula (316) with different L 1 and / or S 1 , as needed, so that the resulting formula (315) The compound contains two or more kinds of S 1 and / or L 1 .
  • a compound of formula (317) of 1 eq it may be first contacted with a compound of formula (316) of 2 eq, and the first S 1 -L is connected to two terminal primary amine groups in the compound of formula (317) Part 1 , then, it is allowed to continue to be in contact with a compound of formula (316) of (n3 + n1-1) eq (the definition and range of n3 and n1 are as described above).
  • (n3 + n1-1) connected to the second portion S 1 -L 1 a secondary amine groups.
  • the compound represented by the formula (317) can be obtained by the following preparation method: the method comprises contacting the compound represented by the formula (318) with an aqueous methylamine solution in the presence of an organic solvent under deprotection reaction conditions to isolate and obtain the formula (317) Compound shown:
  • n1, n3, m1, m2 , m3, R 7, R 10, R 11, R 12, R 13, R 14, R 15 are each as defined and selectable range as described above.
  • the deprotection reaction conditions include a reaction temperature of 0-150 ° C, a reaction time of 5-72 hours, and in one embodiment, a reaction temperature of 20-80 ° C, and a reaction time of 10-30 hours.
  • the organic solvent is selected from the group consisting of alcohol, in one embodiment methanol, ethanol, and isopropanol, and in one embodiment methanol; relative to the compound of formula (318), the amount of the organic solvent is 1 -20 L / mol, in one embodiment 1.5-10 L / mol.
  • the concentration of the methylamine aqueous solution is 30-40% by mass, and the molar ratio of methylamine to the compound represented by formula (318) is 10: 1-500: 1, and in one embodiment, 50: 1-200: 1.
  • the compound of formula (317) can be isolated from the reaction mixture using any suitable separation method.
  • the solvent can be removed by evaporation and the compound of formula (317) can be subsequently separated by chromatography.
  • the solvent can be directly removed to obtain a crude product of the compound of formula (317), which can be used directly in subsequent reactions.
  • the compound represented by the formula (318) can be obtained by the following preparation method: the method comprises combining a compound represented by the formula (319) with triphenylchloromethane (TrCl) and diphenyl in the presence of an organic solvent under substitution reaction conditions. Contacting ethylphenylchloromethane, phenyldiethylphenylchloromethane, or triethylphenylchloromethane, in one embodiment, triphenylchloromethane (TrCl), to isolate a compound represented by formula (318):
  • n1, n3, m1, m2 , m3, R 10, R 11, R 12, R 13, R 14, R 15 are each as defined and selectable range as described above.
  • the substitution reaction condition is that the reaction temperature is 0-100 ° C, the reaction time is 5-72 hours, and in one embodiment, the reaction temperature is 10-40 ° C, and the reaction time is 10-30 hours.
  • Triphenylchloromethane (TrCl), diphenylethylphenylchloromethane, phenyldiethylphenylchloromethane or triethylphenylchloromethane are commercially available. Triphenylchloromethane (TrCl), diphenyl The molar ratio of ethylphenylchloromethane, phenyldiethylphenylchloromethane, or triethylphenylchloromethane to the compound represented by formula (319) is 1: 1-10: 1, and in one embodiment is 1: 1 -3: 1.
  • the organic solvent is one or more of an epoxy-based solvent, an ether-based solvent, a haloalkane-based solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine.
  • the epoxy-based solvent is dioxane and / or tetrahydrofuran in one embodiment
  • the ether-based solvent is diethyl ether and / or methyl tert-butyl ether in one embodiment
  • the haloalkane-based solvent is In one embodiment, one or more of methylene chloride, chloroform, and 1,2-dichloroethane are used.
  • the organic solvent is methylene chloride. Relative to the compound of formula (319), the amount of the organic solvent is 3-50 L / mol, and in one embodiment, 5-20 L / mol.
  • the compound of formula (318) can be isolated from the reaction mixture using any suitable separation method.
  • the solvent can be removed by evaporation and the compound of formula (318) can be subsequently separated by chromatography.
  • the solvent can be removed directly to obtain a crude product of the compound of formula (318), which can be used directly in subsequent reactions.
  • the compound represented by the formula (319) can be obtained by the following preparation method: the method comprises contacting the compound represented by the formula (320) with ethyl trifluoroacetate in an organic solvent under substitution reaction conditions to isolate and obtain the formula (319) Compound shown:
  • n1, n3, m1, m2 , m3, R 10, R 11, R 12, R 13, R 14, R 15 are each as defined and selectable range as described above.
  • the organic solvent is one of acetonitrile, epoxy-based solvent, ether-based solvent, haloalkane-based solvent, dimethyl sulfoxide, N, N-dimethylformamide, and N, N-diisopropylethylamine. Or more.
  • the epoxy-based solvent is dioxane and / or tetrahydrofuran in one embodiment
  • the ether-based solvent is diethyl ether and / or methyl tert-butyl ether in one embodiment
  • the haloalkane-based solvent is In one embodiment, one or more of methylene chloride, chloroform, and 1,2-dichloroethane are used.
  • the organic solvent is acetonitrile. Relative to the compound of formula (320), the amount of the organic solvent is 1-50 L / mol, and in one embodiment is 1-20 L / mol.
  • the substitution reaction condition is that the reaction temperature is 0-100 ° C, the reaction time is 5-72 hours, and in one embodiment, the reaction temperature is 10-40 ° C, and the reaction time is 10-30 hours.
  • the molar ratio of the ethyl trifluoroacetate to the compound represented by formula (320) is 2: 1-10: 1, and in one embodiment is 3: 1-5: 1.
  • the compound of formula (319) can be isolated from the reaction mixture using any suitable separation method.
  • the solvent can be removed directly to obtain a crude product of the compound of formula (319), which can be used directly in subsequent reactions.
  • the siRNA provided by the present disclosure and each adjacent nucleotide in the conjugate containing the siRNA are connected by a phosphodiester bond or a phosphorothioate bond,
  • the non-bridged oxygen or sulfur atom has a negative charge, and it may exist in the form of a hydroxyl group or a mercapto group, and the hydrogen ion in the hydroxyl group or the mercapto group may be partially or completely replaced by a cation.
  • the cation may be any cation, such as one of a metal cation, an ammonium cation NH 4 + , and an organic ammonium cation.
  • the cation is selected from one or more of an alkali metal ion, an ammonium cation formed by a tertiary amine, and a quaternary ammonium cation.
  • the alkali metal ion may be K + or / or Na +
  • the cation formed by the tertiary amine may be ammonium ion formed by triethylamine and / or ammonium ion formed by N, N-diisopropylethylamine. Therefore, the siRNAs and conjugates described in the present disclosure may exist at least partially in the form of a salt.
  • the non-bridged oxygen atom or sulfur atom in the phosphodiester bond or thiophosphodiester bond is at least partially bound to the sodium ion, and the siRNA and the conjugate described in the present disclosure are sodium salts or partial sodium salts. Form exists.
  • a modified nucleotide group can be introduced into the siRNA of the conjugate described in the present disclosure to prepare a nucleoside monomer having a corresponding modification.
  • the methods and methods for introducing modified nucleotide groups into siRNA are also well known to those skilled in the art. All modified nucleoside monomers are commercially available or prepared by known methods.
  • the present disclosure provides the siRNA, pharmaceutical composition, and / or siRNA conjugate provided in the present disclosure for use in the treatment and / or prevention of a pathological condition or disease caused by infection with the hepatitis B virus Use in medicine.
  • the present disclosure provides a method of treating a pathological condition or disease caused by an infection with hepatitis B virus, the method comprising administering to a patient an effective amount of the siRNA, pharmaceutical composition, and / or siRNA provided by the present disclosure. Conjugate.
  • the present disclosure provides a method of inhibiting hepatitis B virus gene expression, the method comprising combining an effective amount of the siRNA, pharmaceutical composition, and / or siRNA conjugate provided by the present disclosure with infection with hepatitis B Contact of viral hepatitis cells.
  • the pathological condition or disease caused by the infection of the hepatitis B virus is selected from chronic liver disease, hepatitis, liver fibrosis disease and liver proliferative disease.
  • the siRNA and / or pharmaceutical composition and / or siRNA conjugate of the present disclosure can be used for the prevention and / or treatment of hepatitis B, or for the manufacture of a medicament for the prevention and / or treatment of hepatitis B.
  • the present disclosure provides the siRNA, pharmaceutical composition, and / or siRNA conjugate provided in the present disclosure in the manufacture of a medicament for treating and / or preventing a pathological condition or disease caused by overexpression of any gene. use.
  • the present disclosure provides a method of treating a pathological condition or disease caused by overexpression of any gene, the method comprising administering to a patient an effective amount of the siRNA, pharmaceutical composition, and / or siRNA conjugate provided by the present disclosure. ⁇ The compound.
  • the present disclosure provides a method of inhibiting gene expression, the method comprising contacting an effective amount of the siRNA, pharmaceutical composition, and / or siRNA conjugate provided by the present disclosure with the cell expressing the gene .
  • the pathological condition or disease caused by the overexpression of any gene is selected from various chronic diseases, inflammation, fibrotic diseases, and proliferative diseases, such as cancer.
  • the siRNA and / or pharmaceutical composition and / or siRNA conjugate of the present disclosure can be used for preventing and / or treating a disease caused by overexpression of any gene, or for preparing for preventing and / or treating an overexpression of any gene. Drugs that cause disease.
  • administration / administration refers to a method or route for siRNA or a pharmaceutical composition by at least partially positioning the siRNA or the pharmaceutical composition or the siRNA conjugate at a desired site to produce a desired effect. Or the siRNA conjugate is placed into the patient.
  • Routes of administration suitable for the methods of the present disclosure include local and systemic administration. Generally speaking, local administration results in more siRNA or pharmaceutical composition or siRNA conjugate being delivered to a specific site compared to the entire body of the patient; whereas systemic administration results in conjugation of the siRNA or pharmaceutical composition or siRNA The substance is delivered to substantially the entire body of the patient.
  • a mode of administration for delivering a drug to the liver is used.
  • Administration to a patient can be by any suitable route known in the art, including, but not limited to, oral or parenteral routes including intravenous, intramuscular, subcutaneous, transdermal, Airway (aerosol), pulmonary, nasal, rectal and topical (including oral and sublingual).
  • oral or parenteral routes including intravenous, intramuscular, subcutaneous, transdermal, Airway (aerosol), pulmonary, nasal, rectal and topical (including oral and sublingual).
  • the frequency of dosing can be daily, weekly, monthly, or once or more per year.
  • the dosage of the siRNA or the pharmaceutical composition or the siRNA conjugate described in the present disclosure may be a conventional dosage in the art, and the dosage may be determined according to various parameters, especially the age, weight and sex of the patient. Toxicity and efficacy can be measured in cell culture or laboratory animals using standard pharmaceutical procedures, such as determining LD50 (a dose that causes 50% of the population to be lethal) and ED50 (a dose that results in 50% of the maximum response intensity in a quantitative response. The middle finger caused the dose when 50% of the subjects had a positive reaction).
  • LD50 a dose that causes 50% of the population to be lethal
  • ED50 a dose that results in 50% of the maximum response intensity in a quantitative response.
  • the middle finger caused the dose when 50% of the subjects had a positive reaction.
  • a range of human dosages can be derived based on data obtained from cell culture analysis and animal studies.
  • the amount of siRNA in the composition is 0.001-50 mg / kg body weight, for example, 0.01-10 mg / kg body weight, 0.05 -5mg / kg body weight or 0.1-3mg / kg body weight;
  • the amount of siRNA can be 0.001-100mg / kg body weight, for example, 0.01 -50 mg / kg body weight, 0.05-20 mg / kg body weight, or 0.1-10 mg / kg body weight.
  • the siRNA and / or pharmaceutical composition and / or siRNA conjugate of the present disclosure into chronic HBV-infected hepatitis cells, it is also possible to suppress the expression of HBV genes in chronic HBV-infected hepatitis cells through an RNA interference mechanism.
  • the cell is a HepG2.2.15 cell.
  • the method provided by the present disclosure is used to inhibit the expression of HBV genes in cells. Regardless of whether the provided siRNA, pharmaceutical composition or siRNA conjugate is used, the amount of siRNA is generally such that it is sufficient to reduce the expression of the target gene and cause the target cell to be expressed. Extracellular concentrations of 1 pM to 1 ⁇ M, or 0.01 nM to 100 nM, or 0.05 nM to 50 nM or to about 5 nM at the surface. The amount required to reach this local concentration will vary with a variety of factors including the method of delivery, the site of delivery, the number of cell layers between the site of delivery and the target cell or tissue, whether the delivery is local or systemic, and the like. The concentration at the delivery site can be significantly higher than the concentration at the surface of the target cell or tissue.
  • the present disclosure provides a kit comprising an siRNA as described above, a pharmaceutical composition as described above, and / or a siRNA conjugate as described above.
  • one container can be used to provide siRNA and at least another container can be used to provide a pharmaceutically acceptable carrier and / or excipient.
  • the kit may also contain other ingredients, such as stabilizers or preservatives. The other ingredients may be included in the kit, but are present in a container different from the container that provides the siRNA and a pharmaceutically acceptable carrier and / or excipient.
  • the kit may include instructions for mixing the siRNA with a pharmaceutically acceptable carrier and / or excipient or other ingredient.
  • the siRNA conjugate may be stored in one container; there may or may not be at least another container for providing or not providing a pharmaceutically acceptable excipient.
  • the kit can also contain other ingredients, such as stabilizers or preservatives. The other ingredients may be included in the kit, but are present in a container different from the container that provides the siRNA conjugate and optional pharmaceutically acceptable excipients.
  • the kit may include instructions for mixing the siRNA conjugate with a pharmaceutically acceptable excipient (for excipients) or other ingredients.
  • the siRNA and a pharmaceutically acceptable carrier and / or excipient, and the siRNA conjugate and optional pharmaceutically acceptable excipient may be provided in any form, such as a liquid form, a dry form Or lyophilized form.
  • the siRNA and a pharmaceutically acceptable carrier and / or excipient and the siRNA conjugate and optional pharmaceutically acceptable excipient are substantially pure and / or sterile.
  • sterile water can be provided in the kits of the present disclosure.
  • conjugate 1-2 (hereinafter, also referred to as L10-siHB3M1SVP conjugate and L10-siHB3M1SP conjugate) was synthesized, and conjugate 3 (hereinafter, also referred to as L10-siHB3M1SPs conjugate) was planned. ⁇ ).
  • the conjugate is a conjugate formed by conjugating L-9 conjugate molecules with siRNAs numbered siHB3M1SVP, siHB3M1SP or siHB3M1SPs, respectively. See Table 3 for the sequence of conjugated siRNA in this conjugate.
  • the L-10 compound was synthesized as follows:
  • GAL-1 N-acetyl-D-galactosamine hydrochloride, CAS number: 1772-03-8, purchased from Ningbo Hongxiang Biochemical Company, 463.8 mmol
  • 100.0 g of GAL-1 N-acetyl-D-galactosamine hydrochloride, CAS number: 1772-03-8, purchased from Ningbo Hongxiang Biochemical Company, 463.8 mmol
  • 100.0 g of GAL-1 N-acetyl-D-galactosamine hydrochloride, CAS number: 1772-03-8, purchased from Ningbo Hongxiang Biochemical Company, 463.8 mmol
  • acetic anhydride purchased from Enox, 5565.6 mmol
  • step (1-1-1a) GAL-2 (35.1 g, 90.0 mmol) obtained in step (1-1-1a) was dissolved in 213 ml of anhydrous 1,2-dichloroethane, and 24.0 g of TMSOTf was added in an ice-water bath and under a nitrogen protective condition. (CAS number: 27607-77-8, purchased from Macleans Corporation, 108.0 mmol), and reacted at room temperature overnight.
  • step (1-1-1b) GAL-3 (26.9 g, 81.7 mmol) obtained in step (1-1-1b) was dissolved in 136 ml of anhydrous 1,2-dichloroethane, and dried 30 g of molecular sieve powder, and then added 9.0 g of 5-hexen-1-ol (CAS number: 821-41-0, purchased from Adamas-beta Company, 89.9 mmol), stirred at room temperature for 30 minutes, added under ice bath and nitrogen protection 9.08 g of TMSOTf (40.9 mmol). The reaction was stirred overnight at room temperature.
  • step (1-1-1c) GAL-4 (14.9 g, 34.7 mmol,) obtained according to the method described in step (1-1-1c) was dissolved in a mixed solvent of 77 ml of dichloromethane and 77 ml of acetonitrile, and 103 ml of deionized water and 29.7 g were added respectively.
  • Sodium periodate (CAS number: 7790-28-5, purchased from Aladdin Company, 138.8 mmol)
  • stirred in an ice water bath for 10 minutes stirred in an ice water bath for 10 minutes, and added ruthenium trichloride (CAS number: 14898-67-0, purchased from Anner) Ji Company, 238 mg, 1.145 mmol), and reacted at room temperature overnight.
  • the reaction solution was added with 300 ml of water for dilution and stirring, and saturated sodium bicarbonate was added to adjust the pH to about 7.5.
  • the organic phase was separated and discarded.
  • the aqueous phase was extracted three times with dichloromethane for 200 ml each time, and the organic phase was discarded.
  • the aqueous phase was adjusted to a pH of about 3 with citric acid solids and extracted three times with 200 ml of dichloromethane.
  • the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated to dryness under reduced pressure to obtain 6.85 g of a white foamy solid product. .
  • the crude M-11-T3 (5.342 g, 10 mmol) was dissolved in 50 ml of dichloromethane. TrCl (3.345 g, 12 mmol) and triethylamine (1.518 g, 15 mmol) were added to the reaction solution, and the reaction was stirred at room temperature for 20 hours. The reaction solution was washed twice with saturated sodium bicarbonate, 20 ml each time, and once with 20 ml saturated brine. The organic phase was dried over anhydrous sodium sulfate. After filtration, the organic solvent was evaporated to dryness under reduced pressure, and the vacuum oil pump was foamed and dried overnight to obtain a crude solid. M-11-T3-Tr 7.763g.
  • step (1-1-3) The crude M-11-T3-Tr (7.763 g, 10 mmol) obtained in step (1-1-3) was dissolved in 100 ml of methanol, and 100 ml of a methylamine aqueous solution (40% by mass) was added, and the reaction was stirred at 50 ° C for 23 hours. Remove insoluble particles by filtration, evaporate the solvent under reduced pressure, add 200 ml of a 1: 1 dichloromethane: methanol mixed solvent, wash with 50 ml of saturated sodium bicarbonate, and extract the aqueous phase three times with dichloromethane (DCM).
  • DCM dichloromethane
  • the reaction solution was diluted with 200 ml of dichloromethane, the organic phase was washed with 100 ml of a saturated sodium bicarbonate solution, and the organic phase was washed with 100 ml of a saturated sodium chloride solution.
  • the organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated to dryness under reduced pressure to obtain a crude product.
  • 200-300 mesh normal phase silica gel column purification, packed with petroleum ether, neutralized the acidity of the silica gel with 1% by weight triethylamine, and eluted with a gradient of dichloromethane: methanol 100: 5-100: 7, and collected the product eluent.
  • step (1-1-5) The L-5-Tr (5.94 g, 3.456 mmol) obtained in step (1-1-5) was dissolved in 69 ml of dichloromethane, and dichloroacetic acid (13.367 g, 103.67 mmol) was added. The reaction was carried out at room temperature for 2 h. 100ml of dichloromethane was used to dilute the reaction solution, and then saturated sodium bicarbonate solution was added to adjust the pH to between 7-8. The aqueous phase was extracted 6 times with 30ml of dichloromethane. The organic phases were combined and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated to dryness under reduced pressure to obtain a crude product.
  • step (1-1-7) L-7 (2.300 g, 1.26 mmol), succinic anhydride (0.378 g, 3.78 mmol) and 4-dimethylaminopyridine (DMAP, 0.462 g, 3.78 mmol) obtained in step (1-1-7) were mixed Dissolve in 13 ml of dichloromethane, add diisopropylethylamine (DIEA, 0.814 g, 6.30 mmol), stir at 25 ° C for 24 h, wash the reaction solution with 5 ml of 0.5 M triethylamine phosphate, and extract the aqueous phase with dichloromethane. Three times, 5 ml each time, combined organic phases were evaporated to dryness under reduced pressure to obtain 2.774 g of crude product.
  • DIEA diisopropylethylamine
  • an L-10 compound is prepared by linking the L-9 conjugated molecule to a solid support.
  • L-10 compound That is, 1.100 g of L-9 conjugated molecules linked to a solid-phase carrier) and a load of 90.8 ⁇ mol / g.
  • CapA and CapB are capping reagent solutions
  • CapA is a 20% by volume N-methylimidazole pyridine / acetonitrile mixed solution, and the volume ratio of pyridine to acetonitrile is 3: 5
  • CapB is a 20% by volume acetic anhydride acetonitrile solution.
  • the sense strand sequences of conjugates 1-3 are the same, so their preparation methods are also the same.
  • each linked nucleoside monomer includes four steps: deprotection, coupling, capping, oxidation or sulfuration.
  • deprotection, coupling, capping, oxidation or sulfuration when two nucleotides are linked by a phosphate ester, when a nucleoside monomer is linked, the four steps include deprotection, coupling, capping, and oxidation.
  • the next nucleoside monomer when the next nucleoside monomer is linked, it includes four steps of protection, coupling, capping, and vulcanization.
  • the synthesis conditions are given as follows:
  • the nucleoside monomer is provided in a 0.1 M acetonitrile solution.
  • the conditions of each step of the deprotection reaction are the same, that is, the temperature is 25 ° C, the reaction time is 70 seconds, and the deprotection reagent is dichloroacetic acid in dichloromethane solution (3%). v / v), the molar ratio of dichloroacetic acid to the 4,4'-dimethoxytrityl protecting group on the solid support was 5: 1.
  • each step of the coupling reaction includes a temperature of 25 ° C, a molar ratio of the nucleic acid sequence linked to the solid phase carrier to the nucleoside monomer of 1:10, and a molar ratio of the nucleic acid sequence linked to the solid phase carrier and the coupling reagent.
  • the ratio is 1:65
  • the reaction time is 600 seconds
  • the coupling reagent is 5-ethylthio-1H-tetrazole in a 0.5M acetonitrile solution.
  • the cap conditions were the same for each step, including a temperature of 25 ° C and a reaction time of 15 seconds.
  • the cap reagent solution is a mixed solution of CapA and CapB in a molar ratio of 1: 1.
  • the oxidation reaction conditions are the same at each step, including a temperature of 25 ° C, a reaction time of 15 seconds, and an oxidation reagent with a concentration of 0.05M iodine.
  • the molar ratio of iodine to the nucleic acid sequence attached to the solid phase support in the coupling step was 30: 1.
  • each step of the sulfurization reaction includes a temperature of 25 ° C., a reaction time of 300 seconds, and a sulfurization reagent of hydrogenated xanthan.
  • the molar ratio of the sulfurization reagent to the nucleic acid sequence attached to the solid-phase support in the coupling step is 120: 1.
  • the cleavage and deprotection conditions are as follows: the synthesized nucleotide sequence with the carrier is added to 25% by weight ammonia water, the amount of ammonia water is 0.5ml / ⁇ mol, the reaction is performed at 55 ° C for 16h, the liquid is removed, and the solution is concentrated to dryness in vacuo.
  • a preparative ion chromatography purification column (Source 15Q) was used to elute the NaCl gradient to complete the purification of the nucleic acid.
  • eluent A 20 mM sodium phosphate (pH 8.1)
  • eluent B 1.5 M sodium chloride, 20 mM sodium phosphate (pH 8.1)
  • elution gradient: eluent A: eluent B 100: 0-50: 50 gradient elution.
  • the product eluents were collected and combined, and then desalted by a reversed-phase chromatography purification column.
  • Detection The purity was measured using ion exchange chromatography (IEX-HPLC), and the molecular weight was analyzed using liquid chromatography-mass spectrometry (LC-MS).
  • the purity was 90.4%; molecular weight, theoretical value 7627.5, found 7626.6.
  • the purity was 94.1%; molecular weight, theoretical value 7627.5, and measured value 7625.1.
  • the measured values are in accordance with the theoretical values, which indicates that the 3′-terminus is a sense chain S conjugated with an L-9 conjugated molecule.
  • Detection The purity was measured by ion exchange chromatography (IEX-HPLC), and the result was 93.1%; the molecular weight was analyzed by liquid chromatography-mass spectrometry (LC-MS). Theoretical value is 6929.17, and the measured value is 6919.9. The measured values are consistent with the theoretical values, indicating that the antisense strand AS with the target sequence is synthesized.
  • the vinyl phosphate modified 2'-methoxy modified uracil nucleoside monomer (VP-Um) was synthesized according to the following method:
  • the VP-U-2 molecule was synthesized as follows:
  • Another solution is to dissolve tetraethyl methylene diphosphate (21.44 g, 74.4 mmol) in 120 ml of THF, cool in an ice bath, add t-BuOK (11.36 g, 101.2 mmol) at the temperature of the ice bath, and react at the temperature of the ice bath first. After 10 minutes, the temperature was raised to room temperature and reacted for 0.5h, and then added to the aforementioned reaction solution. The reaction was completed in about 1h. The reaction was performed at the ice bath temperature for 1h, and then raised to room temperature for 18h. Water was added to quench the reaction, and the aqueous phase was extracted 3 times with 200 ml of dichloromethane.
  • VP-U-4 14.00 g, 22.29 mmol was dissolved in 100 ml of tetrahydrofuran, triethylamine trihydrofluoric acid (17.96 g, 111.45 mmol) was added, and the reaction was completed by stirring at room temperature for 20 h. The solvent was directly evaporated to dryness, then dissolved in dichloromethane and then evaporated to dryness twice, using 50 ml of dichloromethane each time to obtain a crude product.
  • VP-U-5 (391 mg, 1.0 mmol), pyridinium trifluoroacetate (0.232 g, 1.2 mmol), N-methylimidazole (0.099 g, 1.2) were added to 10 ml of anhydrous dichloromethane under argon protection. mmol), bis (diisopropylamino) (2-cyanoethoxy) phosphine (0.452 g, 1.5 mmol), and the reaction was stirred at room temperature for 5 hours.
  • the antisense strand of conjugate 2 differs from the antisense strand of conjugate 1 only by the first nucleotide modification at the 5'-terminus.
  • the last nucleoside monomer attached was 2'-methoxy-modified uracil nucleoside monomer (Um), which was then deprotected, coupled, capped, and oxidized.
  • Um 2'-methoxy-modified uracil nucleoside monomer
  • a CPR-I monomer (Suzhou Jima, Cat # 13-2601-XX) was attached to the 5 'end of the antisense strand to form a 5'-phosphate modification.
  • the general-purpose solid phase carrier used the conditions for deprotection, coupling, capping, oxidation or sulfurization, cutting and deprotection, and purification and desalting conditions are the same as those for the synthesis of the sense chain.
  • the purity was measured by ion exchange chromatography (IEX-HPLC), and the result was 99.0%.
  • the molecular weight was analyzed by LC-MS.
  • the theoretical value was 6924.43, and the measured value was 6924.0. The measured values are consistent with the theoretical values, indicating that the antisense strand AS with the target sequence is synthesized.
  • conjugate 1 the S chain and the AS chain were separately dissolved in water for injection to obtain a 40 mg / mL solution, mixed at an equimolar ratio, heated at 50 ° C for 15 minutes, and cooled at room temperature, and then formed a double-chain structure through hydrogen bonding. .
  • the ultra-pure water (Milli-Q ultra-pure water instrument, self-made, resistivity 18.2 M ⁇ * cm (25 ° C)) was used to dilute the conjugate to a concentration of 0.2 mg / mL, and then a liquid chromatography-mass spectrometer (LC-MS, Liquid Chromatography-Mass Spectrometry (purchased from Waters, Model: LCT Premier) for molecular weight detection.
  • LC-MS liquid chromatography-mass spectrometer
  • the theoretical value S: 7627.5, AS: 6920.17, the measured value S: 7626.9, AS: 6920.1, the measured value is consistent with the theoretical value, indicating that the synthesized conjugate 1 is a target-designed L-9 conjugated molecule Double-stranded nucleic acid sequence.
  • conjugate 1 and conjugate 2 are represented by formula (403).
  • the title conjugate is expected to be prepared, except that: 1) the siRNAs are shown in Table 3 corresponding to conjugates 4-12 and comparative conjugate 1 2)
  • the target sequence contains unmodified nucleotides
  • after ammonia treatment, relative to the amount of single-stranded nucleic acid use 0.4ml / ⁇ mol N-methylpyrrolidone to dissolve the product
  • 0.3 ml / ⁇ mol triethylamine and 0.6 ml / ⁇ mol triethylamine trihydrofluoride were added to remove 2'-TBDMS protection on ribose.
  • the siRNA contained in the comparative conjugate 1 is a negative control siRNA having no inhibitory effect on the HBV gene.
  • the P-10 compound was synthesized as follows:
  • N-dimethylformamide was added GAL-5 (13.43 g, 30.0 mmol), 4-amino acid tert-butyl ester hydrochloride (5.87) obtained according to the method described in (1-1-1) above. g, 30.0mmol), O-benzotriazol-tetramethylurea hexafluorophosphate (13.65g, 36.0mmol) and diisopropylethylamine (11.63g, 90.0mmol), the reaction was stirred at room temperature after homogeneous dissolution 5 hours.
  • the reaction solution was diluted with 20 ml of dichloromethane, the organic phase was washed with 10 ml of a saturated sodium bicarbonate solution, and the organic phase was washed with 10 ml of a saturated sodium chloride solution.
  • the organic phases were combined and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated to dryness under reduced pressure to obtain a crude product.
  • 300 mesh normal phase silica gel column purification, packed with petroleum ether, neutralized the acidity of the silica gel with 1% by weight triethylamine, and eluted with a gradient of dichloromethane: methanol 100: 5-100: 7.
  • the product eluate was collected and decompressed A total of 8.27 g of pure P-6 was obtained by evaporation to dryness.
  • the aqueous phase was extracted twice with 10 ml of dichloromethane, and the organic phases were combined. It was dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated to dryness under reduced pressure, and the crude product was obtained by foaming and drying under vacuum oil pump overnight.
  • 120 g 200-300 mesh normal phase silica gel was used. The acidity of the silica gel was neutralized with 20 ml of triethylamine.
  • the column was equilibrated with petroleum ether containing 1 wt% triethylamine, and petroleum ether: ethyl acetate: dichloromethane: N, N.
  • P-10 was prepared. The difference is that P-9 conjugated molecules are used instead of L-9 conjugated molecules to obtain P-9 conjugated molecules connected to a solid phase carrier.
  • Conjugate 13 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the P-10 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that P10-siHB3M1SVP conjugate can be obtained, and its structure is shown in formula (404).
  • the R-5 compound was synthesized as follows:
  • step (1-1-1b) GAL-3 (26.4 g, 80.2 mmol) obtained according to the method described in step (1-1-1b) was dissolved in 134 ml of anhydrous 1,2-dichloroethane and added 60 g of molecular sieve powder, 7-octen-1-ol (11.3 g, 88.2 mmol) was added, and the reaction was stirred at room temperature for 10 minutes. Trimethylsilyl trifluoromethanesulfonate (8.9 g , 40.1 mmol), and the reaction was stirred at room temperature for 24 hours. Remove by filtration Molecular sieve powder, 500 ml of saturated sodium bicarbonate aqueous solution was added to the filtrate for washing, and the organic phase was separated.
  • the water phase was extracted once with 100 ml of dichloromethane.
  • the organic phases were combined and washed once with 250 ml of saturated brine, and the organic phase was separated and dried over anhydrous sodium sulfate Dry, evaporate the solvent under reduced pressure, and suction-filter to dryness with an oil pump to obtain 33.3 g of GAL-C7-1, a yellow sugar thin product, and proceed to the next oxidation reaction without purification.
  • step (4-1-1) GAL-C7-1 (33.3 g, 72.8 mmol) obtained in step (4-1-1) was dissolved in a mixed solvent of 160 ml of dichloromethane and 160 ml of acetonitrile, and 216 ml of water and sodium periodate solid ( 62.3 g, 291.2 mmol), stirred for 10 minutes in an ice-water bath, and added the catalyst ruthenium trichloride (498 mg, 2.4 mmol) to the room temperature and stirred for 23 hours.
  • the reaction solution was diluted with 200ml of water and stirred.
  • the saturated sodium bicarbonate was added to adjust the pH to 7.5.
  • the organic phase was separated.
  • the aqueous phase was extracted three more times with dichloromethane. The organic phase was discarded.
  • the reaction solution was diluted with 200 ml of dichloromethane, the organic phase was washed with 100 ml of a saturated sodium bicarbonate solution, and the organic phase was washed with 100 ml of a saturated sodium chloride solution.
  • R-2 (2.391 g, 1.532 mmol) and A-1 (2.342 g, 4.596 mmol) were mixed and dissolved in 16 ml of dichloromethane, and 3-diethoxyphosphoryl-1,2,3-benzoazole 4 ( 3H) -one (DEPBT) (1.375 g, 4.596 mmol), diisopropylethylamine (1.188 g, 9.191 mmol) was added, and the reaction was stirred at 25 ° C. for 2 h.
  • DEPBT 3-diethoxyphosphoryl-1,2,3-benzoazole 4
  • diisopropylethylamine (1.188 g, 9.191 mmol
  • the organic phase was washed with 10 ml of saturated sodium bicarbonate, the aqueous phase was extracted 3 times with 10 ml of dichloromethane, the organic phase was washed with 10 ml of saturated brine, and the aqueous phase was extracted twice with 10 ml of dichloromethane.
  • the organic phases were combined It was dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated to dryness under reduced pressure, and the oil was foamed and dried in a vacuum oil pump overnight to obtain a crude product.
  • R-3 (795mg, 0.4074mmol), succinic anhydride (82mg, 0.8148mmol) and 4-dimethylaminopyridine (DMAP, 100mg, 0.8148mmol) were mixed and dissolved in 4ml of dichloromethane, and diisopropylethyl was added.
  • Amine (DIPEA, 100 mg, 0.8148 mmol) was stirred at 25 ° C. for 18 h.
  • the reaction solution was washed with 5 ml of 0.5 M triethylamine phosphate, and the aqueous phase was extracted three times with 5 ml of dichloromethane.
  • the organic phases were combined and evaporated to dryness under reduced pressure to obtain a crude product.
  • R-5 was prepared.
  • R-4 conjugated molecules are used instead of L-9 conjugated molecules to obtain R-4 conjugated molecules connected to a solid phase carrier.
  • Conjugate 14 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the R-5 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that R5-siHB3M1SVP conjugate can be obtained, and its structure is shown in formula (407).
  • Conjugate 15 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the LA-5 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that a LA5-siHB3M1SVP conjugate can be obtained, and its structure is shown in formula (412).
  • the LB-5 compound was synthesized as follows:
  • the aqueous phase was extracted 4 times with 10 ml of dichloromethane each time.
  • the organic phases were combined and evaporated to dryness under reduced pressure to obtain a crude product.
  • 120 g 200-300 mesh normal phase silica gel was used.
  • the acidity of the silica gel was neutralized with 1% by weight triethylamine.
  • the column was equilibrated with dichloromethane.
  • Petroleum ether: ethyl acetate: dichloromethane: methanol 1: 1: 1: 0.2 -1: 1: 1: 1: 1 gradient elution, the solvent was evaporated to dryness under reduced pressure to obtain 4.267 g of pure LB-1.
  • LB-1 (4.697 g, 2.753 mmol, obtained by combining the two batches), 3-amino-1,2-propanediol (313 mg, 3.442 mmol) obtained according to the method described in step (6-1-1) ), 4- (4,6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride (DMTMM, 953mg, 3.442mmol) and N-methylmorpholine (700mg, 6.884mmol ) was added to a mixed solution of 30 ml of acetonitrile and 3 ml of methanol, and the reaction was stirred at room temperature overnight.
  • DTMM 4- (4,6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride
  • N-methylmorpholine 700mg, 6.884mmol
  • the product eluate was collected, and the solvent was removed by concentration to obtain the target product LB. -2 3.27g.
  • LB-3 (822mg, 0.415mmol), succinic anhydride (83g, 0.83mmol) and 4-dimethylaminopyridine (DMAP, 102mg, 0.83mmol) were mixed and dissolved in 4ml of dichloromethane, and DIPEA (270mg, 2.075) was added mmol), the reaction was stirred overnight at 25 ° C.
  • the reaction solution was washed three times with 0.5 M triethylamine phosphate, and the aqueous phase was extracted three times with 2 ml of dichloromethane each time.
  • the organic phases were combined and evaporated to dryness under reduced pressure to obtain a crude product.
  • LB-5 was prepared by the same method as step (1-1-9) in Preparation Example 1. The difference is that LB-4 conjugated molecules are used instead of L-9 conjugated molecules to obtain LB-4 conjugated molecules connected to a solid phase carrier.
  • Conjugate 16 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the LB-5 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that LB5-siHB3M1SVP conjugate can be obtained, and its structure is shown in formula (413).
  • Conjugate 17 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the V-8 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that a V8-siHB3M1SVP conjugate can be obtained, the structure of which is shown in formula (414).
  • the W-8 compound was synthesized as follows:
  • the crude W-1 (5.835 g, 10 mmol) was dissolved in 50 ml of dichloromethane, TrCl (3.345 g, 12 mmol) and triethylamine (1.518 g, 15 mmol) were added to the reaction solution, and the reaction was stirred at room temperature for 20 h.
  • the reaction solution was washed twice with 20 ml of saturated sodium bicarbonate, and once with 20 ml of saturated brine.
  • the organic phases were combined and dried over anhydrous sodium sulfate. After filtration, the organic solvent was evaporated to dryness under reduced pressure, and the vacuum oil pump was foamed and dried overnight to obtain a crude product.
  • Solid W-2 8.012g. Without treatment, the next deprotection reaction was carried out.
  • the crude W-2 (8.012 g, 10 mmol) was dissolved in 100 ml of methanol, and then 100 ml of a methylamine aqueous solution (40 wt%) was added, and the reaction was stirred at 50 ° C. for 23 h. Remove insoluble particles by filtration, evaporate the solvent under reduced pressure, add 200 ml of a 1: 1 DCM-methanol mixed solvent, wash the organic phase with 50 ml of saturated sodium bicarbonate, and extract the aqueous phase three times with dichloromethane, 50 ml each time. The organic phases were combined and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated to dryness under reduced pressure.
  • the oil was dried under vacuum in a vacuum oil pump and purified by a 200-300 mesh normal phase silica gel column.
  • the column was packed with petroleum ether and neutralized with 1% by weight of triethylamine.
  • the product eluate was collected, the solvent was evaporated to dryness under reduced pressure, and the vacuum oil pump was foamed and dried to obtain pure Product W-3 3.062g.
  • W-3 (0.675 g, 1.517 mmol) was mixed with GAL-C7-2 (2.60 g, 5.46 mmol) and dissolved in 47 ml of acetonitrile, then diisopropylethylamine (1.57 g, 12.14 mmol) was added, and finally 3- Diethoxyphosphoryl-1,2,3-benzoazole 4 (3H) -one (DEPBT, 1.816 g, 6.04 mmol) was stirred at room temperature for 2.5 h.
  • the reaction solution was diluted with 100 ml of dichloromethane, the organic phase was washed with 80 ml of a saturated sodium bicarbonate solution, and the organic phase was washed with 80 ml of a saturated sodium chloride solution.
  • the organic phases were combined and washed with 10 ml of saturated brine, and the organic phases were combined and dried over anhydrous sodium sulfate. After filtration, the pressure was reduced. The solvent was evaporated to dryness and vacuum oil pump was foamed and dried overnight to obtain the crude product.
  • W-8 was prepared. The difference is that W-7 conjugated molecules are used instead of L-9 conjugated molecules to obtain W-7 conjugated molecules connected to a solid phase carrier.
  • Conjugate 18 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the W-8 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that a W8-siHB3M1SVP conjugate can be obtained, the structure of which is shown in formula (415).
  • Conjugate 19 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the X-8 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that X8-siHB3M1SVP conjugate can be obtained, and its structure is shown in formula (421).
  • the Z-5 compound was synthesized as follows:
  • the reaction solution was diluted with 100 ml of dichloromethane, the organic phase was washed with 80 ml of a saturated sodium bicarbonate solution, and the organic phase was washed with 80 ml of a saturated sodium chloride solution.
  • MS m / z C98H143N10O33, [M + H] +, theory: 1987.98, found: 1987.90.
  • the aqueous phase was extracted with 10 dichloromethane.
  • the organic phases were combined and washed with 50 ml of saturated brine, and the combined organic phases were anhydrous sodium sulfate. After drying, the solvent was evaporated to dryness under reduced pressure, and the crude oil was obtained by foaming and drying under vacuum oil pump overnight.
  • Z-5 was prepared.
  • Z-4 conjugated molecules are used instead of L-9 conjugated molecules to obtain Z-4 conjugated molecules connected to a solid phase carrier.
  • Conjugate 20 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the Z-5 compound was used instead of the L-10 compound to initiate the sense chain synthesis. It is expected that a Z5-siHB3M1SVP conjugate can be obtained, and its structure is shown in formula (422).
  • the K-4 compound was synthesized as follows:
  • step (1-1-7a) To 60 ml of dichloromethane was added A-1 (3.0 g, 6.0 mmol), PyBOP (6.2 g, 12.0 mmol), HOBt (1.6 g, 2.0 mmol) obtained according to the method described in step (1-1-7a). And diisopropylethylamine (DIEA, 3.9 g, 30.0 mmol), stirred at room temperature for 10 minutes, and then added the above solution to K-0 (5.6 g, 30.0 mmol), and reacted at room temperature for 1 hour and 50 minutes. The reaction solution was poured into 30 ml of a saturated sodium bicarbonate solution, and the aqueous phase was extracted three times with 30 ml of dichloromethane.
  • DIEA diisopropylethylamine
  • K-4 was prepared.
  • the difference is that the K-3 conjugated molecule is used instead of the L-9 conjugated molecule to obtain a K-3 conjugated molecule connected to a solid phase carrier.
  • Comparative conjugate 2 was prepared by the same method as steps (1-2) to (1-4) in Preparation Example 1, except that the K-4 compound was used instead of the L-10 compound to initiate the sense chain synthesis.
  • the K4-siHB3M1SVP conjugate is expected to be obtained, and its structure is shown in formula (423):
  • Nu is the siRNA in the K4-siHB3M1SVP conjugate.
  • siRNA sequences provided in the present disclosure listed in Table 4 were obtained by a conventional solid-phase synthesis method, and equimolar mixtures of the sense and antisense strands were dissolved using DEPC water, followed by conventional annealing to form siRNA double strands.
  • siRNAs 1-4 are siRNAs that specifically target the P gene region of HBV; NC is a negative control siRNA that does not inhibit HBV genes.
  • the siRNA or conjugate of the present disclosure is lyophilized as a solid powder for preservation by standard means.
  • physiological saline NS
  • PB phosphate buffered saline
  • PBS phosphate buffered saline
  • the HEK293A cells used in this experimental example were provided by the Laboratory of Nucleic Acid Technology, Institute of Molecular Medicine, Peking University, and contained 20% fetal bovine serum (FBS, Hyclone) and 0.2 vol% penicillin-antibody Streptomycin, Gibco, Invitrogen) was cultured in DMEM complete medium (Hyclone) and cultured at 37 ° C in an incubator containing 5% CO 2 /95% air.
  • FBS fetal bovine serum
  • penicillin-antibody Streptomycin Gibco, Invitrogen
  • This experimental example examines the on-target activity and off-target effect of conjugate 2 in the in vitro psiCHECK system.
  • GSCM represents the target plasmid
  • PSCM GSSM
  • PSSM off-target plasmid
  • GSCM which contains a target sequence that is completely complementary to the nucleotide sequence 2-19 from the 5 'end of the antisense strand in conjugate 2, and is used to detect the on-target activity of the antisense strand.
  • PSCM which contains a target sequence that is completely complementary to the nucleotide sequence of 1-18 positions from the 5 'end of the sense strand in conjugate 2 and is used to detect the off-target activity of the sense strand.
  • GSSM which contains a target sequence that is completely complementary to the nucleotide sequence 2-8 from the 5 'end of the antisense strand in conjugate 2, and the rest of the target sequence is in conjugate 2
  • the 5 'end of the antisense strand corresponds to the nucleotide sequence from 9-21, and its sequence is completely non-complementary, that is, the nucleotide at any position of 9-21 from the 5' end of the antisense strand in conjugate 2.
  • the nucleotides at the corresponding positions of the target sequence are T, A, C or G, respectively.
  • GSSM was used to detect off-target activity in the seed region of the antisense strand.
  • PSSM which contains a target sequence that is completely complementary to the nucleotide sequence 1-8 from the 5 'end of the sense strand in conjugate 2, and the rest of the target sequence is sense in conjugate 2
  • the nucleotide sequence from the 9-19th position of the 5 'end of the strand corresponds, and its sequence is completely non-complementary, that is, the nucleotide at any position from the 9-19th position of the 5' end of the sense strand in conjugate 2 is G, At C, A or U, the nucleotides at the corresponding positions of the target sequence are T, A, C or G, respectively.
  • PSSM was used to detect off-target activity in the seed region of the sense strand.
  • the target sequence was cloned into the Xho I / Not I site of the psiCHECK TM -2 plasmid.
  • the siRNA conjugate and each of the above plasmids were co-transfected separately.
  • One plasmid corresponds to several groups of conjugate 2 at a specific concentration. 10 ng of the plasmid was transfected using Lipofectamine TM 2000 0.2 ⁇ L.
  • the final concentration of conjugate 2 (calculated as the concentration of siRNA) starts from 1 nM, and is diluted by 11 concentrations to 0.000977 nM; for the other 3 off-target plasmids, the final concentration of conjugate 2 Starting from 10 nM, 10 concentrations were diluted 4-fold to 0.000038 nM. Each group was treated with no siRNA conjugate as a control; each group had 3 replicates.
  • a dual luciferase reporter gene detection kit (Dual Luciferase Reporter Gene Test Kit, Promega, cat. E2940) was used to lyse HEK293A cells according to the instruction manual to detect the dual luciferase reporter gene.
  • the expression level Renal luciferase protein levels were normalized to firefly luciferase protein levels. According to the activity results measured with different siRNA concentrations, Graphpad 5.0 software log (inhibitor) vs. Variable-Slope function was used to fit the dose-response curve, and the IC50 of conjugate 2 targeting GSCM was calculated based on the dose-response curve. value.
  • Y is the expression level of residual mRNA
  • X is the logarithmic value of transfection siRNA conjugate concentration
  • Bot is the Y value at the bottom of the steady state period
  • Top is the Y value at the top of the steady state
  • LogIC50 is the value of X when Y is halfway between the bottom and the top, and HillSlope is the slope of the curve.
  • the negative control siRNA sequence used in this experimental example is as follows:
  • Antisense strand 5’-UfUmUfGAAGUfAUGCCUfCAAGGdTsdT-3 ’(SEQ ID No: 10)
  • siRNA was synthesized by the solid phase phosphoramidite method. A 0.9% sodium chloride aqueous solution was used to prepare the negative control and conjugate 2 into solutions having a concentration of 20 ⁇ M (calculated based on the concentration of siRNA), and recorded as the negative control and conjugate 2 respectively.
  • Preparation of reference sample without lysosomal lysate treatment Take equimolar amounts of conjugate 2 and negative control (20 ⁇ M), 1.5 ⁇ l each, 7.5 ⁇ L sodium citrate aqueous solution (pH 5.0), and 1 ⁇ L deionized water Mix well, denature by adding 30 ⁇ L of 9M urea solution, then add 8 ⁇ L of 6 ⁇ loading buffer and mix well. Immediately freeze in a -80 ° C refrigerator to stop the reaction.
  • the reference sample for the negative control is labeled M1
  • the reference sample for conjugate 2 is labeled M2.
  • a 16% by weight non-denaturing polyacrylamide gel was prepared. 20 ⁇ l of each of the above test sample and reference sample was applied to the gel. After electrophoresis for 10 min at 20 mA constant current, electrophoresis was continued for 30 min at 40 mA constant current. After the electrophoresis was completed, the gel was placed on a shaker and stained with Gelred dye (BioTium, Cat. No. 13G1203) for 10 min. The gel imaging was observed and photographed. The results are shown in Figure 1.
  • siRNA conjugate of the present disclosure shows satisfactory stability in human lysosomal lysate or mouse lysosomal lysate, and can maintain non-degradation for at least 24 hours.
  • Conjugate 2 was formulated with a 0.9% sodium chloride aqueous solution to a concentration of 0.2 mg / ml (calculated based on the concentration of siRNA).
  • Conjugate 1 was formulated with a 0.9% sodium chloride aqueous solution to a concentration of 0.2 mg / ml and 0.06 mg / ml (calculated based on the concentration of siRNA)
  • Hepatitis B virus surface antigen diagnostic kit Enzyme-linked Immunoassay (Shanghai Kehua Biological) was used to detect the serum HBsAg content of mice.
  • Mice with S / COV> 10 were selected and randomly divided into 2 groups (both females). There were 6 rats in each group, which were recorded as the control group and the test group. Animals in each group were injected with various drugs subcutaneously on the first day, and the administration volume was 5 mL / kg. Calculate the dosing volume based on body weight. Among them, the control group was injected with physiological saline; the test group was injected with conjugate 2 at a dose of 1 mg / kg.
  • Real-time quantitative PCR was used to detect the expression level of HBV mRNA in liver tissue.
  • ImProm-II TM reverse transcription kit Promega
  • the kit (Beijing Kangwei Century Biotechnology Co., Ltd.) was used to detect the inhibitory efficiency of siRNA on HBV mRNA expression in liver tissue.
  • GAPDH gene is used as an internal reference gene, and HBV and GAPDH are detected using a primer for HBV and a primer for GAPDH, respectively.
  • HBV gene expression remaining amount (copy number of HBV gene in test group / copy number of GAPDH in test group) / (copy number of HBV gene in control group / copy number of control group GAPDH) ⁇ 100%, the results are shown in Table 7 below .
  • the conjugates of the various examples of the present disclosure show high HBV mRNA inhibitory activity in mice. This also illustrates that the siRNA conjugates of the present disclosure have good in vivo delivery efficiency.
  • conjugate 3-conjugate 12 containing different siRNA lengths and similar modification schemes has Higher mRNA inhibitory activity; it is expected that conjugate 13-conjugate 20 containing the same siRNA and similar conjugated molecules will also have higher mRNA inhibitory activity.
  • HBV model mouse C57B / 6N-Tg (1.28HBV) / Vst (genotype A) used in this experimental example was purchased from Beijing Weidonda Biotechnology Co., Ltd.
  • Conjugate 1 was formulated with a 0.9% sodium chloride aqueous solution to a concentration of 0.6 mg / ml and 0.2 mg / ml (calculated based on the concentration of siRNA).
  • mice Male and female with serum HBsAg content greater than 10 4 COI were randomly divided into 3 groups of 6 mice each, which were recorded as the control group, high-dose group and low-dose group, respectively.
  • Animals in each group were injected with various drugs subcutaneously on the first day, and the administration volume was 5 mL / kg. Calculate the dosing volume based on body weight. All animals were administered in the morning, and if blood collection was required, administration was performed after blood collection.
  • the control group was injected with normal saline; the animals in the test group were injected with different doses of conjugate 1, the high dose group was 3 mg / kg, and the low dose group was 1 mg / kg.
  • Blood was collected from the orbital venous plexus of mice before and at 7, 13, 21, 28, 42, 56, 70, 84, 98, 112 days, 126 days, 140 days, and 154 days after administration. Spot detection of serum HBsAg, HBeAg and HBV DNA levels.
  • Orbital blood is taken about 100 ⁇ l each time, and the serum is not less than 20 ⁇ l after centrifugation, resuspended to 500 ⁇ l with PBS, and sent to Beijing Dean Medical Test Center to detect the serum HBsAg, HBeAg, and HBV DNA content in the serum. Means.
  • test indicators HBsAg, HBeAg, and HBV DNA
  • Normalized level of the indicator to be tested residual content of the indicator to be tested after dosing / content of the indicator to be tested before dosing ⁇ 100%
  • Inhibition rate of the index to be tested (1-normalized level of the index to be tested) ⁇ 100%.
  • the experimental data are all based on The data analysis was performed using Graphpad prism5.0 statistical analysis software. First, the data were tested for normal distribution and homogeneity of variance. Consistent with normal distribution (p> 0.20) and uniform variance (p> 0.10): comparison between multiple groups was performed by LSD method for multiple comparisons with single factor analysis of variance, p ⁇ 0.05 was considered statistically significant; it did not meet normal distribution or variance Inhomogeneity: The non-parametric test Kruskal-Wallis H method is used for comparison between multiple groups. If the Kruskal-wallis H test results are significant (p ⁇ 0.05), the data is subjected to rank conversion and then compared between groups. P ⁇ 0.05 was considered statistically significant.
  • the negative control group administered with physiological saline did not show any inhibitory effect on the serum surface antigen; in contrast, the conjugate 1 at two doses was given HBsAg showed excellent inhibitory effect at different time points after drug administration.
  • the maximum inhibition rate of HBsAg reached 99.8% 13 days after a single administration; the inhibition rate of HBsAg remained above 90% for up to 84 days after administration; as of the end of observation, the inhibition efficiency of HBsAg remained Up to 77.0%.
  • the maximum inhibition rate of HBsAg reached 99.0% 13 days after administration; as of the end of observation at 154 days, the inhibition efficiency of HBsAg still reached 79.4%.
  • conjugate 1 can also inhibit the expression of HBeAg.
  • the expression of HBeAg in the serum was inhibited by about 50% at 70 days after administration.
  • HBeAg was inhibited.
  • the efficiency rebounded to its pre-dose level.
  • conjugate 1 can also effectively inhibit the expression of HBV DNA, and it has maintained a high inhibition rate for an observation period of up to 154 days.
  • the maximum inhibition rate of HBV DNA was 99.2% 13 days after a single administration; the inhibition rate of HBV DNA remained above 90% for up to 84 days after administration; as of the end of observation, HBV DNA The suppression efficiency is still as high as 80.1%.
  • the maximum inhibition rate of HBV DNA was 95.4% 13 days after the administration; as of the observation end of 154 days, the inhibition efficiency of HBV DNA still reached 60.8%.
  • conjugates of the present disclosure can stably and efficiently inhibit the expression of the HBV gene over a long period of time, and in particular have a long-lasting and long-lasting inhibition of surface antigens, showing excellent effects.
  • This experimental example examined the inhibitory activity of each siRNA in Preparation Example 12 in the psiCHECK system in vitro.
  • the detection plasmid GSCM in Experimental Example 1 was co-transfected into HEK239A cells with the siRNAs to be evaluated (siRNAs 1-4 and NC), and the inhibitory activity of siRNA was reflected by the expression level of the double luciferase reporter gene. Specific steps are as follows:
  • siRNA and GSCM plasmids were co-transfected, in which 10 ng of plasmid was transfected in each well, and 0.2 ⁇ L of Lipofectamine TM 2000 was used. , 0.01nM, and 0.001nM. Each group was treated without siRNA as a control. 3 compound holes per group.
  • a dual luciferase reporter gene detection kit (Dual Luciferase Reporter Gene Test Kit, Promega, cat. E2940) was used to lyse HEK293A cells according to the instruction manual to detect the dual luciferase reporter gene. The expression level. Renal luciferase protein levels were normalized to firefly luciferase protein levels. The results are shown in Figure 6.
  • siRNAs 1-4 all had good inhibitory activity in vitro, and the inhibitory rate of each siRNA was above 80% at a concentration of 0.1 nM.
  • SiRNA1-4 (20 ⁇ M, 12 ⁇ l) obtained in Preparation Example 12 were mixed with 108 ⁇ L of 90% human plasma (Human plasma, diluted with PBS), respectively. Incubate at 37 ° C. 10 ⁇ L samples were taken at 0, 2, 4, 6, 24, 48, and 72 hours, and immediately frozen in liquid nitrogen in a -80 ° C refrigerator. After sampling at each time point, 1 ⁇ PBS (pH 7.4) was diluted 5 times and each sample was taken 10 ⁇ L; at the same time, an equimolar amount of siRNA (20 ⁇ M, 1 ⁇ l) was mixed with 49 ⁇ l 1 ⁇ PBS (pH 7.4) Take 10 ⁇ L as a reference sample without human plasma treatment, and record them as “M11-M14”.
  • a 16% by weight non-denaturing polyacrylamide gel was prepared, and the above sample was mixed with 4 ⁇ L of loading buffer (20 mM EDTA, 36% by weight glycerol, 0.06% by weight bromophenol blue), and then loaded under a constant current condition of 20 mA After 20 minutes of electrophoresis, electrophoresis was continued for about 60 minutes under constant current conditions of 40 mA. After the electrophoresis was completed, the gel was placed on a shaker and stained with Gelred dye (BioTium, Cat. No. 13G1203) for 15 minutes. The gel imaging was observed and photographed, and the result is shown in FIG. 7.
  • loading buffer (20 mM EDTA, 36% by weight glycerol, 0.06% by weight bromophenol blue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/CN2019/101656 2018-08-21 2019-08-20 一种核酸、含有该核酸的药物组合物和缀合物及其用途 Ceased WO2020038377A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/269,039 US11918600B2 (en) 2018-08-21 2019-08-20 Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
CN201980010175.1A CN111655849B (zh) 2018-08-21 2019-08-20 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP2021509880A JP2021533800A (ja) 2018-08-21 2019-08-20 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
EP19851738.5A EP3842534A4 (en) 2018-08-21 2019-08-20 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810951752 2018-08-21
CN201810951752.4 2018-08-21
CN201811165363.5 2018-09-30
CN201811165363 2018-09-30

Publications (1)

Publication Number Publication Date
WO2020038377A1 true WO2020038377A1 (zh) 2020-02-27

Family

ID=69593074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/101656 Ceased WO2020038377A1 (zh) 2018-08-21 2019-08-20 一种核酸、含有该核酸的药物组合物和缀合物及其用途

Country Status (5)

Country Link
US (1) US11918600B2 (https=)
EP (1) EP3842534A4 (https=)
JP (1) JP2021533800A (https=)
CN (1) CN111655849B (https=)
WO (1) WO2020038377A1 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2023246750A1 (zh) * 2022-06-21 2023-12-28 正大天晴药业集团股份有限公司 用于抑制乙型肝炎病毒的双链核糖核酸
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US12274752B2 (en) 2017-12-01 2025-04-15 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
EP4265724A4 (en) * 2020-12-18 2025-11-19 Olix Pharmaceuticals Inc ARNI AGENT TO INHIBIT THE EXPRESSION AND USE OF HBV
US12497622B2 (en) 2019-05-22 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
US12540323B2 (en) 2019-05-22 2026-02-03 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12577565B2 (en) 2019-05-24 2026-03-17 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110945130B (zh) 2017-12-01 2024-04-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3083968C (en) 2017-12-01 2024-04-23 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
WO2023116764A1 (zh) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及其用途
CN115058425A (zh) * 2022-06-30 2022-09-16 苏州瑞博生物技术股份有限公司 一种抑制埃博拉病毒的核酸、含有该核酸的药物组合物及其用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096018A1 (en) * 2005-03-09 2006-09-14 Mogam Biotechnology Research Institute Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
WO2010012244A1 (zh) * 2008-08-01 2010-02-04 苏州瑞博生物技术有限公司 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用
US8106022B2 (en) 2007-12-04 2012-01-31 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
WO2012024170A2 (en) * 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN103380113A (zh) 2010-11-15 2013-10-30 生命科技公司 含胺的转染试剂及其制备和使用方法
WO2014025805A1 (en) 2012-08-06 2014-02-13 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated rna agents and process for their preparation
WO2015006740A2 (en) 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
CN105378082A (zh) 2013-05-01 2016-03-02 Isis制药公司 组合物和方法
WO2017015175A1 (en) * 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
WO2017019891A2 (en) * 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
ES2874149T3 (es) 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
AU2007275365A1 (en) 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
AU2014208251B2 (en) 2007-12-04 2016-07-14 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
MX2010008394A (es) 2008-01-31 2010-11-12 Alnylam Pharmaceuticals Inc Metodos optimizados para administracion de arndc focalizando el gen pcsk9.
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
CN101603042B (zh) 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
MX2011004097A (es) 2008-10-15 2011-07-28 Isis Pharmaceuticals Inc Modulacion de la expresion del factor 11.
US20120227119A1 (en) 2008-12-17 2012-09-06 Australian Poultry Crc Pty Ltd Methods of Modulating the Sex of Avians
CA2750561C (en) 2009-01-26 2017-10-10 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
EP2669290A1 (en) 2009-03-02 2013-12-04 Alnylam Pharmaceuticals Inc. Nucleic Acid Chemical Modifications
NZ595891A (en) 2009-04-15 2013-06-28 Isis Pharmaceuticals Inc Modulation of inflammatory responses by factor xi
KR101224828B1 (ko) 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
JP2014501097A (ja) 2009-07-06 2014-01-20 アルナイラム ファーマシューティカルズ， インコーポレイテッド 生物由来物質の産生を高めるための組成物及び方法
CA2677068A1 (en) 2009-09-01 2011-03-01 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2011028938A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
US8653047B2 (en) 2010-01-08 2014-02-18 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CN102140460B (zh) 2010-01-29 2012-12-12 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
CN102140458B (zh) * 2010-01-29 2013-05-22 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
CN102140459B (zh) 2010-01-29 2013-04-03 苏州瑞博生物技术有限公司 一种小干扰核酸和药物组合物及其制药应用
CN102140461B (zh) 2010-01-29 2012-12-05 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
DK2539451T3 (da) 2010-02-24 2016-04-04 Arrowhead Res Corp Sammensætninger til målrettet tilførsel af siRNA
US8691580B2 (en) * 2010-04-09 2014-04-08 Merck Sharp & Dohme Corp. Single chemical entities and methods for delivery of oligonucleotides
KR101869570B1 (ko) 2010-04-28 2018-06-20 아이오니스 파마수티컬즈, 인코포레이티드 변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
CN102344477B (zh) * 2010-07-27 2015-04-08 苏州瑞博生物技术有限公司 一种核苷酸和/或寡核苷酸及其制备方法
CA2812046A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Modified irna agents
WO2012058693A2 (en) 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
ES2605990T3 (es) 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
KR102365961B1 (ko) 2011-03-29 2022-02-23 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
CN102719434A (zh) 2011-03-31 2012-10-10 百奥迈科生物技术有限公司 抑制rna干扰脱靶效应的特异性修饰
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
CN102727907B (zh) 2011-04-13 2015-03-11 苏州瑞博生物技术有限公司 一种小干扰rna药物的给药系统和制剂
CN107854478A (zh) 2011-04-27 2018-03-30 Ionis制药公司 载脂蛋白ciii（apociii）表达的调节
ES2923573T3 (es) 2011-06-21 2022-09-28 Alnylam Pharmaceuticals Inc Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
HRP20181564T1 (hr) 2011-06-30 2018-11-30 Arrowhead Pharmaceuticals, Inc. Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
CN103073726B (zh) 2011-10-26 2015-09-23 苏州瑞博生物技术有限公司 嵌段共聚物与液体组合物和核酸制剂及其制备方法和应用
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
WO2013070771A1 (en) 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Administration of factor xi antisense oligonucleotides
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
FR2998748B1 (fr) 2012-11-23 2015-04-10 Commissariat Energie Atomique Dispositif et procede de retransmission de donnees dans un commutateur reseau
US10125369B2 (en) 2012-12-05 2018-11-13 Alnylam Pharmaceuticals, Inc. PCSK9 iRNA compositions and methods of use thereof
CN104955952A (zh) 2013-01-30 2015-09-30 弗·哈夫曼-拉罗切有限公司 Lna寡核苷酸碳水化合物缀合物
CA3216595A1 (en) 2013-03-14 2014-10-02 Kevin Fitzgerald Complement component c5 irna compositions and methods of use thereof
WO2014182661A2 (en) 2013-05-06 2014-11-13 Alnylam Pharmaceuticals, Inc Dosages and methods for delivering lipid formulated nucleic acid molecules
CN104107437B (zh) 2013-06-09 2015-08-26 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法
EP3564374A1 (en) 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
US9889200B2 (en) 2013-07-31 2018-02-13 Qbi Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
KR102365486B1 (ko) 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절
EP3052627B1 (en) 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
US10607717B2 (en) 2013-11-06 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means of expression profiling
CN111394355A (zh) 2013-12-24 2020-07-10 Ionis制药公司 促血管生成素样3表达的调节
AU2015209481C1 (en) 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2015113922A1 (en) 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Poly oligomer compound with biocleavable conjugates
WO2015148580A2 (en) 2014-03-25 2015-10-01 Arcturus Therapeutics, Inc. Una oligomers having reduced off-target effects in gene silencing
PT3137605T (pt) 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Composições e métodos para modulação da expressão de angiopoietina de tipo 3
EP3862362A3 (en) 2014-05-01 2021-10-27 Ionis Pharmaceuticals, Inc. Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
JP2017522046A (ja) 2014-06-06 2017-08-10 ソルスティス バイオロジクス，リミティッド 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物
EP3736334A1 (en) 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
CN104232644B (zh) 2014-09-03 2016-10-12 浙江大学 一种特异抑制XOR基因表达的siRNA及其应用
TWI710633B (zh) * 2014-11-10 2020-11-21 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
HK1244843A1 (zh) * 2014-11-17 2018-08-17 Alnylam Pharmaceuticals, Inc. 载脂蛋白c3(apoc3)irna组合物及其使用方法
SG10202013032YA (en) 2014-12-15 2021-02-25 Univ Emory Phosphoramidates for the treatment of hepatitis b virus
US10036017B2 (en) 2015-02-17 2018-07-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
JP2018509913A (ja) 2015-03-17 2018-04-12 アローヘッド ファーマシューティカルズ インコーポレイテッド 第ｘｉｉ因子の遺伝子発現を阻害するための組成物と方法
CA2979998A1 (en) 2015-03-20 2016-09-29 Protiva Biotherapeutics, Inc. Compositions and methods for treating hypertriglyceridemia
EA201792263A1 (ru) 2015-04-13 2018-08-31 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102827366B1 (ko) 2015-05-06 2025-07-03 알닐람 파마슈티칼스 인코포레이티드 인자 ＸＩＩ(하게만 인자)(Ｆ12), 칼리크레인 Ｂ, 혈장(플레처 인자) 1(ＫＬＫＢ1) 및 키니노겐 1(ＫＮＧ1) ｉＲＮＡ 조성물 및 그의 이용 방법
CN104922141B (zh) 2015-05-28 2016-05-25 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的siRNA组合物
EP4365291A3 (en) 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
CN107849567B (zh) 2015-06-26 2024-07-23 苏州瑞博生物技术股份有限公司 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用
TW201718620A (zh) 2015-07-27 2017-06-01 阿尼拉製藥公司 黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用方法
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
CN118697894A (zh) 2015-08-25 2024-09-27 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
WO2017055627A1 (en) 2015-10-02 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Apoc3 mutations for the diagnosis and therapy of hereditary renal amyloidosis disease
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
EP3400301A4 (en) 2016-01-08 2019-11-27 Alnylam Pharmaceuticals, Inc. AGAINST FACTOR XII (HAGEMAN FACTOR) (F12) POLYNUCLEOTIDE AGENTS AND METHOD OF USE THEREOF
AU2017213404A1 (en) 2016-01-29 2018-09-20 Kyowa Kirin Co., Ltd. Nucleic acid conjugate
MA45295A (fr) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
IL293308B2 (en) 2016-04-28 2024-12-01 Regeneron Pharma Methods for treating patients with familial hypercholesterolemia
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
JP2019532027A (ja) 2016-08-17 2019-11-07 ソルスティス バイオロジクス，リミティッド ポリヌクレオチド構築物
MX2018009853A (es) 2016-09-02 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos de direccion.
LT3529360T (lt) 2016-10-18 2024-07-25 Novartis Ag Metodai, skirti širdies ir kraujagyslių ligų prevencijai mažinant proproteinų konvertazės subtilizino keksino 9 (pcsk9) baltymo kiekį
CN113652431A (zh) 2016-12-21 2021-11-16 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
CN108239644B (zh) 2016-12-23 2021-05-28 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
CN108265052B (zh) 2016-12-30 2021-05-28 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
AU2018213379A1 (en) 2017-01-30 2019-07-18 Arrowhead Pharmaceuticals Inc. Compositions and methods for inhibition of factor XII gene expression
WO2018191278A2 (en) 2017-04-11 2018-10-18 Arbutus Biopharma Corporation Targeted compositions
CN108929870B (zh) 2017-05-19 2020-01-24 百奥迈科生物技术有限公司 抑制HBV的siRNA分子及其应用
JP2020522265A (ja) 2017-06-02 2020-07-30 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド組成物及びその使用方法
WO2019105403A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3083968C (en) 2017-12-01 2024-04-23 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN111050807B (zh) 2017-12-01 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110945130B (zh) 2017-12-01 2024-04-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
WO2019105437A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3732185B1 (en) 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
CA3118305A1 (en) 2018-11-02 2020-05-07 Arbutus Biopharma Corporation Bivalent targeted conjugates
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CN112423795A (zh) 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN113330117B (zh) 2019-01-18 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN111979237A (zh) 2019-05-22 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
CN111973617A (zh) 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN111973618B (zh) 2019-05-23 2024-02-02 苏州瑞博生物技术股份有限公司 核酸、药物组合物与siRNA缀合物及制备方法和用途
CN111973619B (zh) 2019-05-23 2024-01-30 苏州瑞博生物技术股份有限公司 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
US20220315929A1 (en) 2019-05-24 2022-10-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
CA3140233A1 (en) 2019-05-24 2020-12-03 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate, preparation method and use
EP3978609A4 (en) 2019-05-24 2024-02-07 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096018A1 (en) * 2005-03-09 2006-09-14 Mogam Biotechnology Research Institute Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
US8106022B2 (en) 2007-12-04 2012-01-31 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
WO2010012244A1 (zh) * 2008-08-01 2010-02-04 苏州瑞博生物技术有限公司 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用
WO2012024170A2 (en) * 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN103380113A (zh) 2010-11-15 2013-10-30 生命科技公司 含胺的转染试剂及其制备和使用方法
WO2014025805A1 (en) 2012-08-06 2014-02-13 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated rna agents and process for their preparation
CN105378082A (zh) 2013-05-01 2016-03-02 Isis制药公司 组合物和方法
WO2015006740A2 (en) 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
WO2017015175A1 (en) * 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
WO2017019891A2 (en) * 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. NC_003977.2
"Molecular Cloning", 1989, COLD SPRING HARBOR LABBORATORY PRESS
ANASTASIA KHVOROVAJONATHAN K. WATTS: "The chemical evolution of oligonucleotide therapies of clinical utility", NATURE BIOTECHNOLOGY, vol. 35, no. 3, 2017, pages 238 - 48, XP055410409, DOI: 10.1038/nbt.3765
CAS, no. 14898-67-0
J. AM. CHEM. SOC., vol. 136, 2014, pages 16958 - 16961
J.K. WATTSG. F. DELEAVEYM. J. DAMHA: "Chemically Modified siRNA: tools and applications", DRUG DISCOV TODAY, vol. 13, no. 19-20, 2008, pages 842 - 55
MUTHIAH MANOHARAN: "siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes", ACS CHEMICAL BIOLOGY, vol. 10, no. 5, 2015, pages 1181 - 7, XP055448305, DOI: 10.1021/cb501028c
NUCLEIC ACIDS RESEARCH, vol. 36, no. 7, 2008, pages 2136 - 2151

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US12274752B2 (en) 2017-12-01 2025-04-15 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
US12497622B2 (en) 2019-05-22 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12540323B2 (en) 2019-05-22 2026-02-03 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12577565B2 (en) 2019-05-24 2026-03-17 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP4265724A4 (en) * 2020-12-18 2025-11-19 Olix Pharmaceuticals Inc ARNI AGENT TO INHIBIT THE EXPRESSION AND USE OF HBV
WO2023246750A1 (zh) * 2022-06-21 2023-12-28 正大天晴药业集团股份有限公司 用于抑制乙型肝炎病毒的双链核糖核酸

Also Published As

Publication number Publication date
CN111655849B (zh) 2024-05-10
US20210275564A1 (en) 2021-09-09
EP3842534A4 (en) 2022-07-06
JP2021533800A (ja) 2021-12-09
US11918600B2 (en) 2024-03-05
CN111655849A (zh) 2020-09-11
EP3842534A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
WO2020038377A1 (zh) 一种核酸、含有该核酸的药物组合物和缀合物及其用途
TWI823879B (zh) 核酸、含有該核酸的藥物組合物與綴合物以及製備方法、用途與試劑盒
TWI878211B (zh) ｓｉＲＮＡ綴合物及其用途
TWI810226B (zh) 核酸、含有該核酸的藥物組合物、綴合物及其用途
TWI791696B (zh) 雙鏈寡核苷酸、包含其的藥物組合物與綴合物、及其用途與試劑盒
TWI856002B (zh) 核酸、含有該核酸的藥物組合物與綴合物及其用途與試劑盒
TWI865433B (zh) ｓｉＲＮＡ綴合物及其用途
TWI869331B (zh) ｓｉＲＮＡ綴合物及其用途
WO2020063198A1 (zh) 一种siRNA缀合物及其制备方法和用途
WO2020135581A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2020233680A1 (zh) 核酸、药物组合物与缀合物及制备方法和用途
HK40029116B (zh) 一种核酸、含有该核酸的药物组合物和缀合物及其用途
HK40029116A (en) Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
HK40107173A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK40019842B (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK40019837B (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK40019795B (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK40029120A (en) Sirna conjugate, preparation method therefor and use thereof
HK40019791B (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK40019795A (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19851738

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021509880

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019851738

Country of ref document: EP

Effective date: 20210322

WWW Wipo information: withdrawn in national office

Ref document number: 2019851738

Country of ref document: EP